Document:

Form of Warrant

 Exhibit 4.1 
 THE ISSUANCE OF THIS WARRANT AND THE WARRANT SHARES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE BEEN REGISTERED BY THE COMPANY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REGISTRATION
STATEMENT UNDER THE SECURITIES ACT OF 1933, AS AMENDED (REGISTRATION NO. 333-178211). 

IMMUNOCELLULAR THERAPEUTICS, LTD. 

WARRANT TO PURCHASE COMMON STOCK 

Warrant No.:             
 Number of Shares of Common Stock:                     

Date of Issuance: January,     , 2012 (“Issuance Date”) 

ImmunoCellular Therapeutics, Ltd., a company organized under the laws of Delaware (the “Company”), hereby certifies
that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [Insert name of Holder], the registered holder hereof or its permitted assigns (the “Holder”), is entitled, subject to
the terms set forth below, to purchase from the Company, at the Exercise Price (as defined below) then in effect, upon surrender of this Warrant to Purchase Common Stock (including any Warrants to Purchase Common Stock issued in exchange, transfer
or replacement hereof, the “Warrant”), at any time or times on or after the Initial Exercisability Date, but not after 11:59 p.m., New York time, on the Expiration Date (as defined below),
                    
(                    ) fully paid nonassessable shares of Common Stock, par value $0.0001 per share, subject to adjustment as provided herein
(the “Warrant Shares”). Except as otherwise defined herein, capitalized terms in this Warrant shall have the meanings set forth in Section 16. This Warrant is one of the Warrants to purchase Common Stock (the
“Warrants”) issued pursuant to (i) that certain Underwriting Agreement, dated as of January 9, 2012 (the “Subscription Date”), by and between Cowen and Company, LLC and the Company (the “Underwriting
Agreement”) and (ii) the Company’s Registration Statement on Form S-1 (File number 333-178211) (the “Registration Statement”). 
  

	 	1.	EXERCISE OF WARRANT. 

 (a)
Mechanics of Exercise. Subject to the terms and conditions hereof (including, without limitation, the limitations set forth in Section 1(f)), this Warrant may be exercised by the Holder on any time or times on or after the Initial
Exercisability Date, in whole or in part, by (i) delivery of a written notice, in the form attached hereto as Exhibit A (the “Exercise Notice”), of the Holder’s election to exercise this Warrant and (ii) (A)
payment to the Company of an amount equal to the applicable Exercise Price multiplied by the number of Warrant Shares as to which this Warrant is being exercised (the “Aggregate Exercise Price”) in cash or by wire transfer of
immediately available funds or (B) provided the conditions for 

 
cashless exercise set forth in Section 1(d) are satisfied, by notifying the Company that this Warrant is being exercised pursuant to a Cashless Exercise (as defined in Section 1(d)).
The Holder shall not be required to deliver this Warrant in order to effect an exercise hereunder; provided, however, that in the event that this Warrant is exercised in full or for the remaining unexercised portion hereof, the Holder shall deliver
this Warrant to the Company for cancellation with delivery of the related Exercise Notice. Execution and delivery of the Exercise Notice with respect to less than all of the Warrant Shares shall have the same effect as cancellation of the original
Warrant and issuance of a new Warrant evidencing the right to purchase the remaining number of Warrant Shares. On or before the third (3rd) Trading Day following the date (the “Share Delivery Date”) on which the Company has received
each of the Exercise Notice and the Aggregate Exercise Price (or notice of a Cashless Exercise) and this Warrant, if applicable (the “Exercise Delivery Documents”), the Company shall (X) provided that (i) the shares to be
issued have been registered under the Securities Act of 1933, as amended, (the “Securities Act”), or are freely transferable without restriction or limitation pursuant to Rule 144 under the Securities Act and (ii) the
Company’s transfer agent (the “Transfer Agent”) is participating in The Depository Trust Company (“DTC”) Fast Automated Securities Transfer Program, upon the request of the Holder, credit such aggregate number
of Warrant Shares to which the Holder is entitled pursuant to such exercise to the Holder’s or its designee’s balance account with DTC through its Deposit/Withdrawal At Custodian system, or (Y) if (i) the Transfer Agent is not
participating in the DTC Fast Automated Securities Transfer Program or (ii) the shares to be issued have not been registered under the Securities Act or are not freely transferable without restriction or limitation pursuant to Rule 144 under
the Securities Act, issue and dispatch by overnight courier to the address as specified in the Exercise Notice, a certificate, registered in the Company’s share register in the name of the Holder or its designee, for the number of shares of
Common Stock to which the Holder is entitled pursuant to such exercise. Upon delivery of the Exercise Delivery Documents, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to
which this Warrant has been exercised, irrespective of the date such Warrant Shares are credited to the Holder’s DTC account or the date of delivery of the certificates evidencing such Warrant Shares, as the case may be. If this Warrant is
submitted in connection with any exercise pursuant to this Section 1(a) and the number of Warrant Shares represented by this Warrant submitted for exercise is greater than the number of Warrant Shares being acquired upon an exercise, then the
Company shall as soon as practicable and in no event later than three (3) Trading Days after any exercise and at its own expense, issue a new Warrant (in accordance with Section 7(e)) representing the right to purchase the number of
Warrant Shares issuable immediately prior to such exercise under this Warrant, less the number of Warrant Shares with respect to which this Warrant is exercised. The Company shall pay any and all taxes which may be payable with respect to the
issuance and delivery of Warrant Shares upon exercise of this Warrant; provided, however, that the Company shall not be required to pay any tax which may be payable in respect of any transfer involved in the registration of any certificates for
Warrant Shares or Warrants in a name other than that of the Holder. The Holder shall be responsible for all other tax liability that may arise as a result of holding or transferring this Warrant or receiving Warrant Shares upon exercise hereof.

  
 2 

 (b) Exercise Price. For purposes of this Warrant, “Exercise Price”
means $1.41, subject to adjustment as provided herein. 
 (c) Company’s Failure to Timely Deliver Securities. If,
within three (3) Trading Days after the Company’s receipt of the Exercise Delivery Documents, the Company shall fail to issue and deliver a certificate to the Holder and register such shares of Common Stock on the Company’s share
register or credit the Holder’s balance account with DTC for the number of shares of Common Stock to which the Holder is entitled upon the Holder’s exercise hereunder or pursuant to the Company’s obligation pursuant to clause
(ii) below, and if on or after such Trading Day the Holder purchases (in an open market transaction or otherwise) shares of Common Stock to deliver in satisfaction of a sale by the Holder of shares of Common Stock issuable upon such exercise
that the Holder anticipated receiving from the Company (a “Buy-In”), then the Company shall, within three (3) Trading Days after the Holder’s request and in the Holder’s discretion, either (i) pay cash to the
Holder in an amount equal to the Holder’s total purchase price (including customary brokerage commissions and other reasonable out-of-pocket expenses, if any) for the shares of Common Stock so purchased (the “Buy-In Price”), at
which point the Company’s obligation to deliver such certificate (and to issue such shares of Common Stock) or credit such Holder’s balance account with DTC shall terminate, or (ii) promptly honor its obligation to deliver to the
Holder a certificate or certificates representing such shares of Common Stock or credit such Holder’s balance account with DTC and pay cash to the Holder in an amount equal to the excess (if any) of the Buy-In Price over the product of
(A) such number of shares of Common Stock, times (B) the Weighted Average Price on the date of exercise. 
 (d)
Limited Cashless Exercise. If the Registration Statement (or any subsequent registration statement applicable to the Warrant Shares) permitting the registered issuance of the Warrant Shares is not then effective or the prospectus forming a
part thereof is not then available, then the Holder shall be entitled to utilize cashless exercise, in which event the Company shall issue to the Holder the number of Warrant Shares determined as follows (a “Cashless Exercise”):

 Net Number = (A x B) - (A x C) 
                                   
    B 
 For purposes of the foregoing formula: 

 

	 	A=	 the total number of shares with respect to which this Warrant is then being exercised. 

 

	 	B=	 the Weighted Average Price of the Common Stock (as reported by Bloomberg) for the five (5) consecutive Trading Days ending on the date immediately preceding
the date of the Exercise Notice. 

  

	 	C=	 the Exercise Price then in effect for the applicable Warrant Shares at the time of such exercise. 

  
 3 

 Upon receipt of an Exercise Notice to which this Section 1(d) is applicable, the
Company shall notify the Holder within one (1) Trading Day of such applicability and the calculation of the Warrant Shares issuable upon the noticed exercise of the Warrant utilizing Cashless Exercise, and confirm the Holder’s desire to
complete the exercise of the Warrant pursuant to this Section 1(d). For purposes of Rule 144 promulgated under the Securities Act, it is intended, understood and acknowledged as between the Company and the Holder that the Warrant Shares issued
in a Cashless Exercise shall be deemed to have been acquired by the Holder, and the holding period for the Warrant Shares shall be deemed to have commenced, on the Issuance Date. 

(e) Disputes. In the case of a dispute as to the determination of the Exercise Price or the arithmetic calculation of the Warrant
Shares, the Company shall promptly issue to the Holder the number of Warrant Shares that are not disputed and resolve such dispute in accordance with Section 12. 
 (f) Limitations on Exercises. The Company shall not effect the exercise of this Warrant, and the Holder shall not have the right to exercise this Warrant, to the extent that after giving effect to
such exercise, such Person (together with such Person’s affiliates) would beneficially own in excess of 4.99% (the “Maximum Percentage”) of the shares of Common Stock outstanding immediately after giving effect to such
exercise. For purposes of the foregoing sentence, the aggregate number of shares of Common Stock beneficially owned by such Person and its affiliates shall include the number of shares of Common Stock issuable upon exercise of this Warrant with
respect to which the determination of such sentence is being made, but shall exclude shares of Common Stock which would be issuable upon (i) exercise of the remaining, unexercised portion of this Warrant beneficially owned by such Person and
its affiliates and (ii) exercise or conversion of the unexercised or unconverted portion of any other securities of the Company beneficially owned by such Person and its affiliates (including, without limitation, any convertible notes or
convertible preferred stock or warrants) subject to a limitation on conversion or exercise analogous to the limitation contained herein. Except as set forth in the preceding sentence, for purposes of this paragraph, beneficial ownership shall be
calculated in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended (the “1934 Act”). For purposes of this Warrant, in determining the number of outstanding shares of Common Stock, the Holder may rely
on the number of outstanding shares of Common Stock as reflected in (1) the Company’s most recent Form 10-K, Form 10-Q, Current Report on Form 8-K or other public filing with the Securities and Exchange Commission, as the case may be,
(2) a more recent public announcement by the Company or (3) any other notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. For any reason at any time, upon the written or oral request
of the Holder, the Company shall within one (1) Business Day confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares Common Stock shall be determined after
giving effect to the conversion or exercise of securities of the Company, including the Warrants, by the Holder and its affiliates since the date as of which such number of outstanding shares of Common Stock was reported. By written notice to the
Company, the Holder may from time to time increase or decrease the Maximum Percentage to any other 

  
 4 

 
percentage not in excess of 9.99% specified in such notice; provided that (i) any such increase will not be effective until the sixty-first (61st) day after such notice is delivered to the Company, and
(ii) any such increase or decrease will apply only to the Holder and not to any other holder of Warrants. The provisions of this Section 1(f) shall be construed and implemented in a manner otherwise than in strict conformity with the terms
hereof to correct this Section 1(f) (or any portion hereof) which may be defective or inconsistent with the intended beneficial ownership limitation herein contained or to make changes or supplements necessary or desirable to properly give
effect to such limitation. 
 (g) No Fractional Shares or Scrip. No fractional shares or scrip representing fractional
shares shall be issued upon the exercise of this Warrant. As to any fraction of a share that the Holder would otherwise be entitled to purchase upon such exercise, the Company shall pay a cash adjustment in respect of such final fraction in an
amount equal to such fraction multiplied by the Exercise Price. 
 (h) Reservation of Warrant Shares. The Company
covenants that it will at all times reserve and keep available out of the aggregate of its authorized but unissued and otherwise unreserved Common Stock, solely for the purpose of enabling it to issue Warrant Shares upon exercise of this Warrant as
herein provided, the number of Warrant Shares which are then issuable and deliverable upon the exercise of this entire Warrant, free from preemptive rights or any other contingent purchase rights of persons other than the Holder (after giving effect
to the adjustments and restrictions of Section 2, if any). The Company covenants that all Warrant Shares so issuable and deliverable shall, upon issuance and the payment of the applicable Exercise Price in accordance with the terms hereof, be
duly and validly authorized, issued and fully paid and nonassessable. The Company will take all such action as may be necessary to assure that such shares of Common Stock may be issued as provided herein without violation of any applicable law or
regulation, or of any requirements of any securities exchange or automated quotation system upon which the Common Stock may be listed. 
 2. ADJUSTMENT OF EXERCISE PRICE AND NUMBER OF WARRANT SHARES. The Exercise Price and the number of Warrant Shares shall be adjusted from time to time as follows: 

(a) Voluntary Adjustment By Company. The Company may at any time during the term of this Warrant reduce the then current Exercise
Price to any amount and for any period of time deemed appropriate by the Board of Directors of the Company. 
 (b) Adjustment
upon Subdivision or Combination of shares of Common Stock. If the Company at any time on or after the Subscription Date subdivides (by any stock split, stock dividend, recapitalization or otherwise) one or more classes of its outstanding shares
of Common Stock into a greater number of shares, the Exercise Price in effect immediately prior to such subdivision will be proportionately reduced and the number of Warrant Shares will be proportionately increased. If the Company at any time on or
after the Subscription Date combines (by combination, reverse stock split or otherwise) one or more classes of its outstanding shares of Common Stock into a smaller number of shares, the Exercise Price in

  
 5 

 
effect immediately prior to such combination will be proportionately increased and the number of Warrant Shares will be proportionately decreased. Any adjustment under this Section 2(b)
shall become effective at the close of business on the date the subdivision or combination becomes effective. 
 (c) Other
Events. If any event occurs of the type contemplated by the provisions of Section 2(b) but not expressly provided for by such provisions (including, without limitation, the granting of stock appreciation rights, phantom stock rights or
other rights with equity features), then the Company’s Board of Directors will make an appropriate adjustment in the Exercise Price and the number of Warrant Shares so as to protect the rights of the Holder; provided that no such adjustment
pursuant to this Section 2(c) will increase the Exercise Price or decrease the number of Warrant Shares as otherwise determined pursuant to this Section 2. 
 3. RIGHTS UPON DISTRIBUTION OF ASSETS. If the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) (the “Distributed
Property”) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off,
reclassification, corporate rearrangement, scheme of arrangement or other similar transaction), at any time after the issuance of this Warrant, then, in each such case the Holder shall be entitled upon exercise of this Warrant for the purchase of
any or all of the Warrant Shares, to receive the amount of Distributed Property which would have been payable to the Holder had the Holder been the holder of such Warrant Shares on the record date for the determination of stockholders entitled to
such Distributed Property. The Company will at all times set aside in escrow and keep available for distribution to such holder upon exercise of this Warrant a portion of the Distributed Property to satisfy the distribution to which such Holder is
entitled pursuant to the preceding sentence. 
 4. PURCHASE RIGHTS; FUNDAMENTAL TRANSACTIONS. 

(a) Purchase Rights. In addition to any adjustments pursuant to Section 2 above, if at any time the Company grants, issues or
sells any Options, Convertible Securities or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of Common Stock (the “Purchase Rights”), then the Holder will be entitled upon
exercise of this Warrant for the purchase of any or all of the Warrant Shares, to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had the Holder been the
holder of such Warrant Shares on the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for
the grant, issue or sale of such Purchase Rights. The Company will at all times set aside in escrow and keep available for distribution to such holder upon exercise of this Warrant a portion of the Purchase Rights to satisfy the rights to which such
Holder is entitled pursuant to the preceding sentence. 
 (b) Fundamental Transactions. The Company shall not enter into
or be party to a Fundamental Transaction unless the Successor Entity assumes in writing all of the 

  
 6 

 
obligations of the Company under this Warrant in accordance with the provisions of this Section (4)(b), including agreements to deliver to each holder of the Warrants in exchange for such
Warrants a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant, including, without limitation, an adjusted exercise price equal to the value for the shares of Common Stock
reflected by the terms of such Fundamental Transaction, and exercisable for a corresponding number of shares of capital stock equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any
limitations on the exercise of this Warrant) prior to such Fundamental Transaction. Upon the occurrence of any Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such
Fundamental Transaction, the provisions of this Warrant referring to the “Company” shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the obligations of the Company
under this Warrant with the same effect as if such Successor Entity had been named as the Company herein. Upon consummation of the Fundamental Transaction, the Successor Entity shall deliver to the Holder confirmation that there shall be issued upon
exercise of this Warrant at any time after the consummation of the Fundamental Transaction, in lieu of the shares of Common Stock (or other securities, cash, assets or other property) issuable upon the exercise of the Warrant prior to such
Fundamental Transaction, such shares of the publicly traded common stock or common shares (or its equivalent) of the Successor Entity (including its Parent Entity) which the Holder would have been entitled to receive upon the happening of such
Fundamental Transaction had this Warrant been converted immediately prior to such Fundamental Transaction, as adjusted in accordance with the provisions of this Warrant. In addition to and not in substitution for any other rights hereunder, prior to
the consummation of any Fundamental Transaction pursuant to which holders of shares of Common Stock are entitled to receive securities or other assets with respect to or in exchange for shares of Common Stock (a “Corporate Event”),
the Company shall make appropriate provision to insure that the Holder will thereafter have the right to receive upon an exercise of this Warrant at any time after the consummation of the Corporate Event but prior to the Expiration Date, in lieu of
shares of Common Stock (or other securities, cash, assets or other property) purchasable upon the exercise of this Warrant prior to such Corporate Event, such shares of stock, securities, cash, assets or any other property whatsoever (including
warrants or other purchase or subscription rights) which the Holder would have been entitled to receive upon the happening of such Corporate Event had this Warrant been exercised immediately prior to such Corporate Event. The provisions of this
Section 4(b) shall apply similarly and equally to successive Fundamental Transactions and Corporate Events and shall be applied without regard to any limitations on the exercise of this Warrant. 

5. NON-CIRCUMVENTION. The Company hereby covenants and agrees that the Company will not, by amendment of its governing documents,
or through any reorganization, transfer of assets, consolidation, merger, scheme of arrangement, dissolution, issue or sale of securities, or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of
this Warrant, and will at all times in good faith carry out all the provisions of this Warrant and take all action as may be required to protect the rights of the Holder. Without limiting the generality of the foregoing, the Company (i) shall
not increase the par value of any 

  
 7 

 
shares of Common Stock receivable upon the exercise of this Warrant above the Exercise Price then in effect, (ii) shall take all such actions as may be necessary or appropriate in order that
the Company may validly and legally issue fully paid and nonassessable shares of Common Stock upon the exercise of this Warrant, and (iii) shall, so long as any of the Warrants are outstanding, take all action necessary to reserve and keep
available out of its authorized and unissued shares of Common Stock, solely for the purpose of effecting the exercise of the Warrants, the number of shares of Common Stock as shall from time to time be necessary to effect the exercise of the
Warrants then outstanding (without regard to any limitations on exercise). 
 6. WARRANT HOLDER NOT DEEMED A STOCKHOLDER.
Except as otherwise specifically provided herein, the Holder, solely in such Person’s capacity as a holder of this Warrant, shall not be entitled to vote or receive dividends or be deemed the holder of share capital of the Company for any
purpose, nor shall anything contained in this Warrant be construed to confer upon the Holder, solely in such Person’s capacity as the Holder of this Warrant, any of the rights of a stockholder of the Company or any right to vote, give or
withhold consent to any corporate action (whether any reorganization, issue of stock, reclassification of stock, consolidation, merger, conveyance or otherwise), receive notice of meetings, receive dividends or subscription rights, or otherwise,
prior to the issuance to the Holder of the Warrant Shares which such Person is then entitled to receive upon the due exercise of this Warrant. In addition, nothing contained in this Warrant shall be construed as imposing any liabilities on the
Holder to purchase any securities (upon exercise of this Warrant or otherwise) or as a stockholder of the Company, whether such liabilities are asserted by the Company or by creditors of the Company. Notwithstanding this Section 6, the Company
shall provide the Holder with copies of the same notices and other information given to the stockholders of the Company generally, contemporaneously with the giving thereof to the stockholders. 

7. REISSUANCE OF WARRANTS. 
 (a) Registration of Warrant. The Company shall register this Warrant, upon the records to be maintained by the Company for that purpose (the “Warrant Register”), in the name of the
record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent
actual notice to the contrary. The Company shall also register any transfer, exchange, reissuance or cancellation of any portion of this Warrant in the Warrant Register. 
 (b) Transfer of Warrant. If this Warrant is to be transferred, the Holder shall surrender this Warrant to the Company, whereupon the Company will forthwith issue and deliver upon the order of the
Holder a new Warrant (in accordance with Section 7(e)), registered as the Holder may request, representing the right to purchase the number of Warrant Shares being transferred by the Holder and, if less than the total number of Warrant Shares
then underlying this Warrant is being transferred, a new Warrant (in accordance with Section 7(e)) to the Holder representing the right to purchase the number of Warrant Shares not being transferred. 

  
 8 

 (c) Lost, Stolen or Mutilated Warrant. Upon receipt by the Company of evidence
reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant, and, in the case of loss, theft or destruction, of any indemnification undertaking by the Holder to the Company in customary form and, in the case
of mutilation, upon surrender and cancellation of this Warrant, the Company shall execute and deliver to the Holder a new Warrant (in accordance with Section 7(e)) representing the right to purchase the Warrant Shares then underlying this
Warrant. 
 (d) Exchangeable for Multiple Warrants. This Warrant is exchangeable, upon the surrender hereof by the Holder
at the principal office of the Company, for a new Warrant or Warrants (in accordance with Section 7(e)) representing in the aggregate the right to purchase the number of Warrant Shares then underlying this Warrant, and each such new Warrant
will represent the right to purchase such portion of such Warrant Shares as is designated by the Holder at the time of such surrender; provided, however, that no Warrants for fractional shares of Common Stock shall be given. 

(e) Issuance of New Warrants. Whenever the Company is required to issue a new Warrant pursuant to the terms of this Warrant, such
new Warrant (i) shall be of like tenor with this Warrant, (ii) shall represent, as indicated on the face of such new Warrant, the right to purchase the Warrant Shares then underlying this Warrant (or in the case of a new Warrant being
issued pursuant to Section 7(b) or Section 7(d), the Warrant Shares designated by the Holder which, when added to the number of shares of Common Stock underlying the other new Warrants issued in connection with such issuance, does not
exceed the number of Warrant Shares then underlying this Warrant), (iii) shall have an issuance date, as indicated on the face of such new Warrant which is the same as the Issuance Date, and (iv) shall have the same rights and conditions
as this Warrant. 
 8. NOTICES. Whenever notice is required to be given under this Warrant, unless otherwise provided
herein, such notice shall be given in accordance with Section 15 of the Underwriting Agreement. The Company shall provide the Holder with prompt written notice of all actions taken pursuant to this Warrant, including in reasonable detail a
description of such action and the reason therefor. Without limiting the generality of the foregoing, the Company will give written notice to the Holder (i) promptly upon any adjustment of the Exercise Price, setting forth in reasonable detail,
and certifying, the calculation of such adjustment and (ii) at least fifteen (15) days prior to the date on which the Company closes its books or takes a record (A) with respect to any dividend or distribution upon the shares of
Common Stock, (B) with respect to any grants, issuances or sales of any Options, Convertible Securities or rights to purchase stock, warrants, securities or other property pro rata to holders of shares of Common Stock or (C) for
determining rights to vote with respect to any Fundamental Transaction, dissolution or liquidation; provided in each case that such information shall be made known to the public prior to or in conjunction with such notice being provided to the
Holder. 
 9. AMENDMENT AND WAIVER. Except as otherwise provided herein, the provisions of this Warrant may be amended
and the Company may take any action herein prohibited, or omit to perform any act herein required to be performed by it, only if the Company 

  
 9 

 
has obtained the written consent of the Required Holders; provided that no such action may increase the exercise price of any Warrant or decrease the number of shares or class of stock obtainable
upon exercise of any Warrant without the written consent of the Holder. No such amendment shall be effective to the extent that it applies to less than all of the holders of the Warrants then outstanding. 

10. GOVERNING LAW. This Warrant shall be governed by and construed and enforced in accordance with, and all questions concerning
the construction, validity, interpretation and performance of this Warrant shall be governed by, the internal laws of the State of New York, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of New
York or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than the State of New York. 
 11. CONSTRUCTION; HEADINGS. This Warrant shall be deemed to be jointly drafted by the Company and the Holder and shall not be construed against any person as the drafter hereof. The headings of
this Warrant are for convenience of reference and shall not form part of, or affect the interpretation of, this Warrant. 
 12.
DISPUTE RESOLUTION. In the case of a dispute as to the determination of the Exercise Price or the arithmetic calculation of the Warrant Shares, the Company shall submit the disputed determinations or arithmetic calculations via facsimile
within two (2) Business Days of receipt of the Exercise Notice giving rise to such dispute, as the case may be, to the Holder. If the Holder and the Company are unable to agree upon such determination or calculation of the Exercise Price or the
Warrant Shares within five (5) Business Days of such disputed determination or arithmetic calculation being submitted to the Holder, then the Company shall, within two (2) Business Days submit via facsimile (a) the disputed
determination of the Exercise Price to an independent, reputable investment bank selected by the Company and approved by the Holder or (b) the disputed arithmetic calculation of the Warrant Shares to the Company’s independent, outside
accountant. The Company shall use commercially reasonable efforts to cause the investment bank or the accountant, as the case may be, to perform the determinations or calculations and notify the Company and the Holder of the results no later than
ten Business Days from the time it receives the disputed determinations or calculations. Such investment bank’s or accountant’s determination or calculation, as the case may be, shall be binding upon all parties absent demonstrable error.
The expenses of the investment bank and accountant will be borne by the Company unless the investment bank or accountant determines that the determination of the Exercise Price or the arithmetic calculation of the Warrant Shares by the Holder was
incorrect, in which case the expenses of the investment bank and accountant will be borne by the Holder. 
 13. REMEDIES,
OTHER OBLIGATIONS, BREACHES AND INJUNCTIVE RELIEF. The remedies provided in this Warrant shall be cumulative and in addition to all other remedies available under this Warrant, at law or in equity (including a decree of specific performance
and/or other injunctive relief), and nothing herein shall limit the right of the Holder to pursue actual damages for any failure by the Company to comply with the terms of this Warrant. The Company acknowledges that a breach by it of its obligations
hereunder will cause irreparable harm to the Holder and that the remedy at law for any such breach may be inadequate. The Company therefore agrees that, in the event of any such breach or threatened breach, the holder of this Warrant shall be
entitled, in addition to all other available remedies, to 

  
 10 

 
seek an injunction restraining any breach, without the necessity of showing economic loss and without any bond or other security being required. 

14. TRANSFER. This Warrant may be offered for sale, sold, transferred or assigned without the consent of the Company. This Warrant
and the Warrant Shares have been registered by the Company with the Commission pursuant to the Registration Statement. 
 15.
SEVERABILITY. If any provision of this Warrant is prohibited by law or otherwise determined to be invalid or unenforceable by a court of competent jurisdiction, the provision that would otherwise be prohibited, invalid or unenforceable shall
be deemed amended to apply to the broadest extent that it would be valid and enforceable, and the invalidity or unenforceability of such provision shall not affect the validity of the remaining provisions of this Warrant so long as this Warrant as
so modified continues to express, without material change, the original intentions of the parties as to the subject matter hereof and the prohibited nature, invalidity or unenforceability of the provision(s) in question does not substantially impair
the respective expectations or reciprocal obligations of the parties or the practical realization of the benefits that would otherwise be conferred upon the parties. The parties will endeavor in good faith negotiations to replace the prohibited,
invalid or unenforceable provision(s) with a valid provision(s), the effect of which comes as close as possible to that of the prohibited, invalid or unenforceable provision(s). 

16. CERTAIN DEFINITIONS. For purposes of this Warrant, the following terms shall have the following meanings: 

(a) “Bloomberg” means Bloomberg Financial Markets. 

(b) “Business Day” means any day other than Saturday, Sunday or other day on which commercial banks in The City of New
York are authorized or required by law to remain closed. 
 (c) “Closing Bid Price” means, for any security as
of any date, the last closing bid price for such security on the Principal Market, as reported by Bloomberg, or, if the Principal Market begins to operate on an extended hours basis and does not designate the closing bid price, then the last bid
price of such security prior to 4:00:00 p.m., New York time, as reported by Bloomberg, or, if the Principal Market is not the principal securities exchange or trading market for such security, the last closing bid price of such security on the
principal securities exchange or trading market where such security is listed or traded as reported by Bloomberg, or if the foregoing do not apply, the last closing bid price of such security in the over-the-counter market on the electronic bulletin
board for such security as reported by Bloomberg, or, if no closing bid price is reported for such security by Bloomberg, the average of the bid prices of any market makers for such security as reported in the “pink sheets” by Pink Sheets
LLC (formerly the National Quotation Bureau, Inc.). If the Closing Bid Price cannot be calculated for a security on a particular date on any of the foregoing bases, the Closing Bid Price of such security on such date shall be the fair market value
as mutually determined by the Company and the Holder. If the Company and the Holder are unable to agree upon the fair 

  
 11 

 
market value of such security, then such dispute shall be resolved pursuant to Section 12. All such determinations to be appropriately adjusted for any stock dividend, stock split, stock
combination or other similar transaction during the applicable calculation period. 
 (d) “Common Stock” means
(i) the Company’s shares of Common Stock, par value $0.0001 per share, and (ii) any share capital into which such Common Stock shall have been changed or any share capital resulting from a reclassification of such Common Stock.

 (e) “Convertible Securities” means any stock or securities (other than Options) directly or indirectly
convertible into or exercisable or exchangeable for shares of Common Stock. 
 (f) “Effective Date” means the
effective date of the Registration Statement. 
 (g) “Eligible Market” means the Principal Market, The NASDAQ
Capital Market, The NASDAQ Global Market, The NASDAQ Global Select Market, The New York Stock Exchange, Inc., or The NYSE Amex and the markets operated by the OTC Markets Group, Inc. 

(h) “Expiration Date” means January     , 2017. 

(i) “Fundamental Transaction” means that (A) the Company shall, directly or indirectly, in one or more related
transactions, (i) consolidate or merge with or into (whether or not the Company is the surviving corporation) another Person, or (ii) sell, assign, transfer, convey or otherwise dispose of all or substantially all of the properties or
assets of the Company to another Person, or (iii) allow another Person to make a purchase, tender or exchange offer that is accepted by the holders of more than the 50% of the outstanding shares of Common Stock (not including any shares of
Common Stock held by the Person or Persons making or party to, or associated or affiliated with the Persons making or party to, such purchase, tender or exchange offer), or (iv) consummate a stock purchase agreement or other business
combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with another Person whereby such other Person acquires more than the 50% of the outstanding shares of Common Stock (not including any
shares of Common Stock held by the other Person or other Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock purchase agreement or other business combination), or (v) reorganize,
recapitalize or reclassify its Common Stock or (B) any “person” or “group” (as these terms are used for purposes of Sections 13(d) and 14(d) of the 1934 Act) is or shall become the “beneficial owner” (as defined in
Rule 13d-3 under the 1934 Act), directly or indirectly, of 50% of the aggregate ordinary voting power represented by issued and outstanding shares of Common Stock. 
 (j) “Initial Exercisability Date” means the Issuance Date. 
 (k)
“Options” means any rights, warrants or options to subscribe for or purchase shares of Common Stock or Convertible Securities. 

  
 12 

 (l) “Parent Entity” of a Person means an entity that, directly or
indirectly, controls the applicable Person and whose common shares or common stock or equivalent equity security is quoted or listed on an Eligible Market, or, if there is more than one such Person or Parent Entity, the Person or Parent Entity with
the largest public market capitalization as of the date of consummation of the Fundamental Transaction. 
 (m)
“Person” means an individual, a limited liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization, any other entity and a government or any department or agency thereof. 

(n) “Principal Market” means the OTC Bulletin Board. 

(o) “Required Holders” means the holders of the Warrants representing at least a majority of the shares of Common Stock
underlying the Warrants then outstanding. 
 (p) “Successor Entity” means the Person (or, if so elected by the
Required Holders, the Parent Entity) formed by, resulting from or surviving any Fundamental Transaction or the Person (or, if so elected by the Required Holders, the Parent Entity) with which such Fundamental Transaction shall have been entered
into. 
 (q) “Trading Day” means any day on which the Common Stock is traded on the Principal Market, or, if
the Principal Market is not the principal trading market for the Common Stock, then on the principal securities exchange or securities market on which the Common Stock is then traded; provided that “Trading Day” shall not include any day
on which the Common Stock is scheduled to trade on such exchange or market for less than 4.5 hours or any day that the Common Stock is suspended from trading during the final hour of trading on such exchange or market (or if such exchange or market
does not designate in advance the closing time of trading on such exchange or market, then during the hour ending at 4:00:00 p.m., New York time). 
 (r) “Weighted Average Price” means, for any security as of any date, the dollar volume-weighted average price for such security on the Principal Market during the period beginning at
9:30:01 a.m., New York time (or such other time as the Principal Market publicly announces is the official open of trading), and ending at 4:00:00 p.m., New York time (or such other time as the Principal Market publicly announces is the official
close of trading), as reported by Bloomberg through its “Volume at Price” function or, if the foregoing does not apply, the dollar volume-weighted average price of such security in the over-the-counter market on the electronic bulletin
board for such security during the period beginning at 9:30:01 a.m., New York time (or such other time as the Principal Market publicly announces is the official open of trading), and ending at 4:00:00 p.m., New York time (or such other time as the
Principal Market publicly announces is the official close of trading), as reported by Bloomberg, or, if no dollar volume-weighted average price is reported for such security by Bloomberg for such hours, the average of the highest Closing Bid Price
and the lowest closing ask price of any of the market makers for such security as reported in the “pink sheets” by Pink Sheets LLC (formerly the National Quotation Bureau, Inc.). If the Weighted Average Price cannot be calculated for a

  
 13 

 
security on a particular date on any of the foregoing bases, the Weighted Average Price of such security on such date shall be the fair market value as mutually determined by the Company and the
Holder. If the Company and the Holder are unable to agree upon the fair market value of such security, then such dispute shall be resolved pursuant to Section 12 with the term “Weighted Average Price” being substituted for the term
“Exercise Price.” All such determinations shall be appropriately adjusted for any stock dividend, stock split, stock combination or other similar transaction during the applicable calculation period. 

[Signature Page Follows] 

  
 14 

 IN WITNESS WHEREOF, the Company has caused this Warrant to Purchase Common Stock to
be duly executed as of the Issuance Date set out above. 
  

					
	ImmunoCellular Therapeutics, Ltd.
		
	 By:
	 	  

		 	Name:	 	  

		 	Title:	 	  

  
 15 

 EXHIBIT A 
 EXERCISE NOTICE 
 TO BE EXECUTED BY THE REGISTERED HOLDER TO EXERCISE
THIS 
 WARRANT TO PURCHASE COMMON STOCK 
 IMMUNOCELLULAR THERAPEUTICS, LTD. 
 The undersigned holder hereby exercises
the right to purchase                      of the Common Stock (“Warrant Shares”) of ImmunoCellular Therapeutics, Ltd., a
company organized under the laws of the State of Delaware (the “Company”), evidenced by the attached Warrant to Purchase Common Stock (the “Warrant”). Capitalized terms used herein and not otherwise defined shall
have the respective meanings set forth in the Warrant. 
 1. Form of Exercise Price. The Holder intends that payment of
the Exercise Price shall be made as: 

                     a
“Cash Exercise” with respect to                      Warrant Shares; 

                     and/or

                     a
“Cashless Exercise” with respect to                      Warrant Shares. 

2. Payment of Exercise Price. In the event that the holder has elected a Cash Exercise with respect to some or all of the Warrant
Shares to be issued pursuant hereto, the holder shall pay the Aggregate Exercise Price in the sum of
$                             to the Company in accordance with the terms of the Warrant. 

3. Delivery of Warrant Shares. The Company shall deliver to the holder
             Warrant Shares in accordance with the terms of the Warrant. 
 4. Representation and Warranty. Notwithstanding anything to the contrary contained herein, this Exercise Notice shall constitute a representation by the Holder of the Warrant submitting this
Exercise Notice that, after giving effect to the exercise provided for in this Exercise Notice, such Holder (together with its affiliates) will not have beneficial ownership (together with the beneficial ownership of such Person’s affiliates)
of a number of shares of Common Stock which exceeds the Maximum Percentage (as defined in the Warrant) of the total outstanding shares of Common Stock of the Company as determined pursuant to the provisions of Section 1(f) of the Warrant.

 Date:                     
    ,              

                         
                            
   Name of Registered Holder 
  

							
	 By:    
	  	  
	 		 	
		  	 Name:
	 		 	
		  	 Title:
	 		 	

  
 16 

 ACKNOWLEDGMENT 

The Company hereby acknowledges this Exercise Notice and hereby directs [Insert name of Transfer Agent] to issue the above
indicated number of shares of Common Stock in accordance with the Transfer Agent Instructions dated                  , 20     from the
Company and acknowledged and agreed to [Insert name of Transfer Agent]. 
  

					
	ImmunoCellular Therapeutics, Ltd.
		
	 By:
	 	  

		 	Name:	 	  

		 	Title:Collaboration Agreement

 Exhibit 10.1 
 ***Text Omitted and Filed Separately 
 with the Securities and Exchange
Commission. 
 Confidential Treatment Requested 
 Under 17 C.F.R. Sections 200.80(b)(4) 
 and 240.24b-2 

COLLABORATION AGREEMENT 
 THIS COLLABORATION AGREEMENT (the “Agreement”) is entered into as of June 23, 2011 (the
“Effective Date”), by and between NOVUS INTERNATIONAL, INC., a Delaware corporation (“Novus”), with its principal place of business at 20 Research
Park Drive, St. Charles, Missouri 63304, and VERENIUM CORPORATION, a Delaware corporation (“Verenium”), with its principal place of business at 4955 Directors Place, San
Diego, California 92121. Verenium and Novus are referred to herein collectively as the “Parties,” and each is referred to herein as a “Party.” 

WHEREAS, Novus engages in the research, development manufacture, and sale of animal health and nutrition products
for poultry, pork, beef, dairy, aquaculture, and companion animal industries on a worldwide basis; 

WHEREAS, Verenium is an industrial biotechnology company with proprietary technology that it uses to develop and
commercialize high performance enzymes for use in a broad array of industrial processes; and 
 WHEREAS,
Novus and Verenium wish to enter into a collaborative relationship to develop, manufacture and commercialize certain enzyme products on the terms and subject to the conditions set forth herein. 

NOW, THEREFORE, in consideration of the mutual covenants and promises hereinafter set
forth, the receipt and sufficiency of which the Parties hereby acknowledge, the Parties hereby agree as follows: 
 ARTICLE 1

 DEFINITIONS 
 1.1 “Accounting Standards” shall mean generally accepted accounting principles in the United States (U.S. GAAP), or internationally, as appropriate, consistently applied and shall mean
the international financial reporting standards (“IFRS”) at such time as IFRS becomes the generally accepted accounting standard and applicable laws require that a Party use IFRS. 

1.2 “Affiliate” means any entity that directly or indirectly controls or is controlled by or is under common control
with any other entity. For the purpose of this definition and the definition of Subsidiary below, “control” means ownership, directly or through one or more Affiliates, of greater than 50% (or such lesser percentage which is the maximum
allowed to be owned by a foreign entity in a particular jurisdiction) of the shares of stock or other equity interests entitled to vote for the election of directors, status as a general partner in any partnership, or any other arrangement whereby
an entity controls or has the right to control the board of directors or equivalent governing body of a corporation or other entity. 

  
 1 

 1.3 “Animal Feed Enzyme” means [...***...] Enzymes consisting of
[...***...] selected from among the Candidate Enzymes under Section 2.1. 
 1.4 “Annual Commercialization
Budget” shall have the meaning set forth in Section 2.4(b). 
 1.5 “Annual Development Budget”
shall have the meaning set forth in Section 2.2(a). 
 1.6 “Audited Party” shall have the meaning set
forth in Section 4.7(a). 
 1.7 “[...***...]” shall have the meaning set forth in
Section 5.2(b). 
 1.8 “Candidate Enzymes” means Enzymes proposed for potential selection through the
Candidate Selection Process, which shall include at least [...***...]. 
 1.9 “Candidate Selection
Process” means the process for selection of Animal Feed Enzymes under Section 2.1. 
 1.10 “Change of
Control” with respect to a Party means (a) a merger, tender offer, share exchange, reorganization, consolidation or other transaction between such Party and a Third Party, in which the direct or indirect beneficial owners of the voting
securities of such Party immediately prior to such transaction would hold 50% or less of the voting securities or other voting interests of the surviving or resulting entity immediately after such transaction (in either case, whether directly or
indirectly through any parent entity), or (b) any sale or other disposition of all or substantially all of the assets of such Party to a Third Party, other than such a sale or other disposition of all or substantially all of such assets of such
Party to an entity of which more than 50% of the voting securities or other voting interests of such entity are beneficially owned after such sale or disposition by shareholders of such Party (in either case, whether directly or indirectly through
any parent entity). 
 1.11 “Claim” shall have the meaning set forth in Section 10.3. 

1.12 “COGS” means, with respect to Animal Feed Enzymes and Products, the aggregate of internal and external costs of a
Party or its Affiliate to manufacture, formulate and supply such Animal Feed Enzymes and Products, calculated as follows: (a) to the extent that a Party or its Affiliate performs all or any part of the manufacturing, formulating, supplying or
distributing of such Animal Feed Enzymes or Products, the direct material costs (only for Animal Feed Enzymes but not for any enzyme or product in a Product that is not an Animal Feed Enzyme), direct labor costs, storage, packaging and shipping for,
plus manufacturing overhead (which may include facilities’ start-up costs, the costs of audits, insurance, and manufacturing administrative and facilities costs, including allocable depreciation and repairs and maintenance of existing capital
assets and new capital assets that were approved by the Management Team), reasonably allocable to, such manufacturing, formulating or supplying of such Animal Feed Enzymes or Products (which may include unsuccessful or low yielding production runs,
production runs for inventory build-up, and excess or idle capacity), all determined in 

  

					
		  	2.	  	
		  		  	***Confidential Treatment Requested

 
accordance with the Accounting Standards; and (b) to the extent that manufacturing, formulating or supplying of such Animal Feed Enzymes or Products is performed by a Third Party, the
out-of-pocket expenses paid by a Party or its Affiliate for such manufacturing (only for Animal Feed Enzymes but not for any enzyme or product in a Product that is not an Animal Feed Enzyme), formulating or supplying activities (including, to the
extent included in the fees charged by such Third Party, direct raw materials and rent for fermentors (only for Animal Feed Enzymes but not for any enzyme or product in a Product that is not an Animal Feed Enzyme), repairs and maintenance of capital
assets, costs for unsuccessful or low yielding production runs, production runs for inventory build-up, and excess capacity due to inaccurate forecasting by customers), and the reasonably allocated direct labor costs incurred by a Party or its
Affiliate in managing and overseeing the Third Party relationship, determined in accordance with the Accounting Standards. COGS shall also include royalties, license or other fees paid by a Party or its Affiliate to Third Parties to license Patent
Rights or other intellectual property rights specifically for the manufacture and supply of such Animal Feed Enzymes (to the extent not already included in the out-of-pocket expenses under clause (b) above); provided, that any such amounts that
are included in COGS will not be included in any other category of Development Costs or Shared Expenses so as not to double count such amounts. For clarification, COGS excludes any capital investment to build or construct a manufacturing facility.

 1.13 “Commercialization Plan” shall have the meaning set forth in Section 2.4(b). 

1.14 “Confidential Information” means any information and materials furnished or made available by one Party to the
other Party pursuant to or as contemplated by this Agreement or the NDA, whether orally or in written, electronic or other form. Confidential Information shall include the terms of this Agreement, and any scientific or technical information,
Know-How, Inventions, technical data or specifications, testing methods, business or financial information, research and development activities and results, product and marketing plans, and customer and supplier information of the disclosing Party,
including any such information that become known to the other Party during visits to the facilities of the disclosing Party. For clarification, all Novus Technology shall be the Confidential Information of Novus, and all Verenium Technology shall be
the Confidential Information of Verenium. 
 1.15 “Credit Amount” shall have the meaning set forth in
Section 4.3(c). 
 1.16 “Development Costs” means, with respect to Animal Feed Enzymes and Products, the
following costs incurred after the Effective Date directly in connection with development (including expression, formulation, quality, animal trials, regulatory and bioprocess development, as well as additional evolution of existing Enzymes), and
filing for and obtaining regulatory approval of such Animal Feed Enzymes and Products in accordance with this Agreement and the Development Plan: (a) all out-of-pocket expenses paid by either Party or its Affiliates to Third Parties (including
any filing or registration fees paid to a Regulatory Authority or other governmental authority and costs of legal analysis including but not limited to landscape analyses and freedom to operate opinions as agreed by the Management Team), which shall
be without markup, (b) COGS for development, scale-up activities and production runs of Animal Feed Enzymes and Products, which shall be without markup, (c) COGS for supply of Animal Feed Enzymes and Products for product registrations and
regulatory activities, which shall be without 

  
 3 

 
markup, and (d) all direct and reasonable internal costs incurred by either Party or its Affiliates (determined using the applicable FTE rate as set forth in the Development Plan), all as
determined from the books and records of the Parties in accordance with the Accounting Standards. For clarification, Development Costs may include costs set forth in this Section 1.15 incurred with respect to a Product after first commercial
sale of such Product, such as costs for strain improvement and fermentation optimization. 
 1.17 “Development
Exclusivity Field” shall have the meaning set forth in Section 2.2(g). 
 1.18 “Development Exclusivity
Period” shall have the meaning set forth in Section 2.2(g). 
 1.19 “Development Plan” shall have
the meaning set forth in Section 2.2(a). 
 1.20 “Disclosing Party” means that Party that discloses or
makes available Confidential Information to the other Party. 
 1.21 “Enzyme” means any of the following types
of enzymes discovered or developed by Verenium, which enzymes are expressed or produced through a microbial fermentation process, and nucleic acids encoding such enzymes: [...***...]. 

1.22 “Enzyme Information” shall have the meaning set forth in Section 2.1. 

1.23 “Excluded Enzyme” means any of [...***...]. 

1.24 “Field” means (a) any health and nutrition application associated with monogastric animals,
ruminants, aquaculture, equine and/or companion animals, (b) [...***...], and (c) animal health and nutrition applications related to the enzyme treatment of [...***...]. 

1.25 “FTE” shall mean the equivalent of one full year of work on a full time basis by a scientist, employee or
independent contractor of the applicable Party possessing skills and experience necessary to carry out the activities by a Party contemplated by this Agreement, determined in accordance with the such Party’s normal policies and procedures.

 1.26 “Indemnitee” shall have the meaning set forth in Section 8.3. 

1.27 “Indemnitor” shall have the meaning set forth in Section 8.3. 

1.28 “Inventions” shall have the meaning set forth in Section 5.2(a). 

  

					
		  	4.	  	
		  		  	***Confidential Treatment Requested

 1.29 “Joint Brand” means any new brand adopted by the Management Team
pursuant to Section 2.4(d) and specific to an Animal Feed Enzyme or Product, which does not include any existing or future name or brand adopted or used by Novus or Verenium with products or services other than an Animal Fees Enzyme or Product.

 1.30 “Joint Brand License” shall have the meaning set forth in Section 3.1. 

1.31 “Know-How” means any and all know-how, trade secrets, inventions, data, processes, procedures, devices, methods,
formulas, media, lines, reagents, compounds, protocols and marketing and other information, including improvements thereon, whether or not patentable. 
 1.32 “License” shall have the meaning set forth in Section 3.1. 
 1.33 “Losses” shall have the meaning set forth in Section 8.1. 
 1.34 “Major Market” means any of [...***...]. 
 1.35
“Management Team” means the group responsible for advice and oversight with regard to activities of the Parties pursuant to this Agreement as established pursuant to Section 2.5. 

1.36 “Material Activity” shall have the meaning set forth in Section 5.4(b)(i). 

1.37 “Materials” shall have the meaning set forth in Section 2.2(d). 

1.38 “NDA” means the Non-Disclosure Agreement between the Parties, dated February 17, 2011. 

1.39 “Net Sales” shall mean the gross invoice price of Product sold by Novus or any of its Affiliates, less the
following deductions from such gross amounts which are actually incurred and included in gross amounts invoiced: 
 (a)
price reductions, credits and allowances actually granted in the sale of such Product provided no financial or other in-kind contributions (or promise thereof) are received by Novus or any of its Affiliates as compensation for such adjustments;
and 
 (b) sales, value added, or similar taxes measured by the invoiced amount, when included in the invoice.

 Net Sales shall not include sales between Novus and its Affiliates; provided, however, that if Novus and/or any such
Affiliate is the end-user of the Product, then Net Sales shall include sales of the Product to Novus or such Affiliate, and the sales price hereunder shall be deemed to be the greater of the price actually charged to Novus or such Affiliate, or the
sales price that would be charged to a Third Party for a similar application, resale or use in an arms’ length transaction. 

  

					
		  	5.	  	
		  		  	***Confidential Treatment Requested

 1.40 “ [...***...]” shall have the meaning set forth in
Section 5.2(d). 
 1.41 “Novus Know-How” means all Know-How that is solely or jointly owned by or licensed
to Novus, with the right to license or sublicense, as of the Effective Date or during the Term and that is necessary for the use, offer for sale, sale, import or export of any Animal Feed Enzyme or Product in the Field. Novus Know-How excludes Novus
Patent Rights and Novus Manufacturing IP. 
 1.42 “Novus Manufacturing IP” means all Know-How and Patent Rights
that are solely or jointly owned by or licensed to Novus, with the right to license or sublicense, as of the Effective Date or during the Term and that are necessary for the manufacture of any Animal Feed Enzyme or Product in the Field. 

1.43 “[...***...]” shall have the meaning set forth in Section 5.2(e). 

1.44 “Novus Patent Rights” shall mean all Patent Rights that are solely or jointly owned by or licensed to Novus, with
the right to license or sublicense, as of the Effective Date or during the Term and that are necessary for the use, offer for sale, sale, import or export of any Animal Feed Enzyme or Product in the Field. Novus Patent Rights excludes Novus
Manufacturing IP. 
 1.45 “Novus Technology” shall mean the Novus Know-How and the Novus Patent Rights.

 1.46 “Patent Rights” means all patent applications and issued and subsisting patents, including all
provisionals, converted provisionals, requests for continued examination, substitutions, divisionals, continuations, continuations-in-part, reissues, reexaminations, extensions, supplementary protection certificates, confirmations, registrations,
revalidations, revisions, and additions of or to any of the foregoing. 
 1.47 “Product” means any product or
composition containing, incorporating or comprised of any form of an Animal Feed Enzyme, including, without limitation, any product that is a [...***...]. 
 1.48 “Profit/Loss” means, with respect to a Product, the amount equal to (a) Net Sales of such Product less (b) the Shared Expenses for such Product. In the event that a Product
contains both one or more Animal Feed Enzymes and one or more active ingredients other than the Animal Feed Enzyme(s) which other active ingredient(s) add a significant contribution to Net Sales of such Product apart from the Animal Feed Enzyme(s),
the Parties shall in good faith negotiate the calculation of Profit/Loss (including both the Net Sales and Shared Expenses) with respect to such Product by determining the relative value to the end user of the contribution of the Animal Feed
Enzyme(s) in the Product, compared to the relative value to the end user of the contribution of the other active ingredient(s) in such product. 
 1.49 “Profit/Loss Statement” shall have the meaning set forth in Section 4.3(b). 

  

					
		  	6.	  	
		  		  	***Confidential Treatment Requested

 1.50 “Progress Report” shall have the meaning set forth in
Section 2.2(c). 
 1.51 “Receiving Party” means the Party that receives or observes Confidential
Information of the other Party. 
 1.52 “Regulatory Authority” means any national, regional, state or local
regulatory agency, department, bureau, commission, council or other governmental entity whose review and/or approval is necessary for the manufacture, packaging, use, storage, import, export, distribution, promotion, marketing, offer for sale and
sale of a Product. 
 1.53 “Representatives” shall have the meaning set forth in Section 11.1. 

1.54 “Requesting Party” shall have the meaning set forth in Section 4.7(a). 

1.55 “Sales Targets” shall have the meaning set forth in Section 2.4(c). 

1.56 “Shared Expenses” means, with respect to a Product, the sum of (a) the Parties’ sales, marketing and
administrative costs (which may include, without limitation, costs of providing technical support and customer assays, advertising, promotion (such as promotional material and goods, print production/reprints, advertising agency fees, advertising
space, direct mail, trade show expenses and free samples), sales commissions and salaries), regulatory expenses (to the extent not included in Development Costs) and costs of legal analysis (but excluding litigation expenses), in each case to the
extent allocable to such Product as approved by the Management Team; (b) COGS for such Product, including the Animal Feed Enzymes used in such Product; (c) the cost of delivery of Animal Feed Enzymes used in such Product from the supplier
to Novus to the extent such cost is not otherwise included in COGS, and (d) the cost of distribution of such Product, including inventory, handling, packaging and shipping costs to the extent such cost is not paid for or reimbursed by the
customer, all as determined from the books and records of the Parties in accordance with the Accounting Standards. 
 1.57
“Standstill Period” shall have the meaning set forth in Section 11.1. 
 1.58 “Subsidiary”
means any entity that is controlled, directly or indirectly, by a Party to this Agreement. 
 1.59 “Term” shall
have the meaning set forth in Section 9.1. 
 1.60 “[...***...]” shall have the meaning set
forth in Section 9.5(b). 
 1.61 “Territory” shall mean worldwide. 

1.62 “Third Party” means any person or entity other than Novus and its Affiliates or Verenium and its Affiliates.

 1.63 “Third Party Claims” shall have the meaning set forth in Section 8.1. 

  

					
		  	7.	  	
		  		  	***Confidential Treatment Requested

 1.64 “Verenium Core Technology” means any and all
technologies solely or jointly owned by or licensed to Verenium [...***...]. 
 1.65
“[...***...]” shall have the meaning set forth in Section 5.2(b). 
 1.66 “Verenium
Know-How” means all Know-How that is solely or jointly owned by or licensed to Verenium, with the right to license or sublicense, as of the Effective Date or during the Term and that is necessary for the use, offer for sale, sale, import or
export of any Animal Feed Enzyme or Product in the Field. Verenium Know-How excludes Verenium Patent Rights, Verenium Manufacturing IP and Verenium Core Technology. 
 1.67 “Verenium Manufacturing IP” means all Know-How and Patent Rights that are solely or jointly owned by or licensed to Verenium, with the right to license or sublicense, as of the
Effective Date or during the Term and that are necessary for the manufacture of any Animal Feed Enzyme or Product in the Field. Verenium Manufacturing IP excludes Verenium Core Technology. 

1.68 “[...***...]” shall have the meaning set forth in Section 5.2(c). 

1.69 “Verenium Patent Rights” means all Patent Rights that are solely or jointly owned by or licensed to Verenium, with
the right to license or sublicense, as of the Effective Date or during the Term and that are necessary for the use, offer for sale, sale, import or export of any Animal Feed Enzyme or Product in the Field, including the Patent Rights listed in a
separate letter agreement. Verenium Patent Rights exclude Verenium Manufacturing IP and Verenium Core Technology. 
 1.70
“Verenium Technology” shall mean the Verenium Know-How and the Verenium Patent Rights. 
 ARTICLE 2

 COLLABORATION 
 2.1 Candidate Selection Process. The initial Development Plan agreed to by the Parties as of the Effective Date shall identify the Candidate Enzymes and available information about such Candidate
Enzymes, and shall describe the information about such Candidate Enzymes to be generated in the course of activities performed pursuant to Section 2.2 to enable selection of Candidate Enzymes as Animal Feed Enzymes (the “Enzyme
Information”). Verenium shall provide the Management Team with the Enzyme Information about each Candidate Enzyme that is reasonably necessary for the Candidate Selection Process. Novus, in consultation with the Management Team, shall
diligently review and consider the Enzyme 

  

					
		  	8.	  	
		  		  	***Confidential Treatment Requested

 
Information in order for designation of a Candidate Enzyme as an Animal Feed Enzyme to be made by mutual written agreement of the Parties within [...***...] after the date the Enzyme
Information is submitted to the Management Team, which may be extended up to an additional [...***...] or as otherwise agreed to by the Management Team. If the Parties have discussed the designation of a Candidate Enzyme as an Animal Feed
Enzyme pursuant to this Section 2.1 but have not designated an Animal Feed Enzyme by mutual written agreement, a Party may provide written notice to the other Party of the proposed designation of a Candidate Enzyme as an Animal Feed Enzyme, and
if the other Party does not provide written notice to the proposing Party of such other Party’s agreement or disagreement with such designation within [...***...] after receipt of such notice from the proposing Party, then the proposing
Party shall have final decision-making authority with respect to selection of such Candidate Enzyme as an Animal Feed Enzyme. Upon written designation of a Candidate Enzyme as an Animal Feed Enzyme in accordance with this Section 2.1, the
License with respect to such Animal Feed Enzyme shall automatically become effective. Any Candidate Enzyme that is not designated as an Animal Feed Enzyme in accordance with this Section 2.1 shall automatically cease to be a Candidate Enzyme
and shall not be considered an Animal Feed Enzyme, and Novus shall have no further rights hereunder with respect to such Enzyme. In the event that, within the category of [...***...], as applicable, no Candidate Enzyme is selected as an Animal
Feed Enzyme taking into account legal or scientific analysis, the Parties shall discuss in good faith the possibility of identifying another Candidate Enzyme within such category for evaluation. 

2.2 Development and Regulatory Activities. 
 (a) Development Plan. The Parties shall prepare and implement a plan for development and regulatory activities with respect to each Animal Feed Enzyme and related Products in the Field (each such
plan, including the initial plan, as may be amended by written agreement of the Parties, the “Development Plan”) in accordance with this Section 2.2. Each Development Plan will include an annual budget with key
performance parameters and estimated costs, which annual budget will be updated quarterly to reflect changes in required activity levels (as may be amended by written agreement of the Parties, the “Annual Development
Budget”). In consultation with the Management Team, Verenium shall prepare and submit to Novus a draft Development Plan with respect to an Animal Feed Enzyme and related Product for review and discussion within [...***...] of the
selection of such Animal Feed Enzyme (or such longer period as agreed by the Parties in writing); provided that, if Verenium does not submit a draft Development Plan by the end of such period, Novus shall prepare and submit such Development Plan to
Verenium. Each Development Plan with respect to an Animal Feed Enzyme and related Product shall describe in detail the development and regulatory activities to be performed by the Parties with respect to such Animal Feed Enzyme and related Product,
including, without limitation (i) a technical summary and schedule for the work to be performed; and (ii) each Party’s level of effort in terms of FTEs and related FTE rates. Any updates to any Development Plan (including any change
to any Annual Development Budget) proposed by either Party to the other Party shall be submitted for review and discussion. Each Development Plan (including any Annual Development Budget), and any amendment to any Development Plan (including any
Annual Development Budget) shall require the written approval of both Novus and Verenium. 

  

					
		  	9.	  	
		  		  	***Confidential Treatment Requested

 (b) Conduct of Activities. The Parties will diligently conduct the development and
regulatory activities as specified in each Development Plan. Each Party shall conduct such activities in a professional manner and shall use commercially reasonable efforts to meet the time schedules and objectives contemplated in each Development
Plan. 
 (c) Progress Reports. The Parties shall document efforts in carrying out their development and regulatory
activities under each Development Plan in the form of a quarterly report (“Progress Report”), or more frequent reports or discussions if needed to communicate significant results in a timely manner to the Management Team.
Each Progress Report shall communicate, at a minimum, the status of the applicable development and regulatory activities, issues that need to be addressed by the Parties, and planned action items. 

(d) Limited Use of Materials Provided by Each Party. Each Party agrees that it will use materials provided to it by the other
Party (collectively, the “Materials”) only for the activities conducted by such Party pursuant to and in accordance with this Agreement and as specified in each Development Plan, and each Party agrees that it will not use
such Materials for any other purpose or use whatsoever. 
 (e) Regulatory Filings. Verenium shall, in consultation with
Novus, have primary responsibility for preparing all regulatory submissions worldwide for the registration of the Animal Feed Enzymes and Products in the Field, including, without limitation, as appropriate for the market, compiling any dossiers and
all filings required by the Biodiversity Convention and other legislation related to the ownership or use of biological resources. The Management Team shall determine, on a jurisdiction-by-jurisdiction basis, whether Verenium or Novus (or its
Subsidiary) shall be the party named on applications for registration of the Animal Feed Enzymes and/or Products in the Field, and such Party shall, in consultation with the other Party, file the application for registration of the Animal Feed
Enzymes and/or Products in the Field in the applicable jurisdiction; provided that, to the extent the laws, rules or regulations of the applicable jurisdiction require that the name of the commercializing party be listed on the registration, then
the application for registration in such jurisdiction will be filed in the name of Novus (or its Subsidiary). Verenium shall, in consultation with Novus, have primary responsibility for managing the process of obtaining registration of the Animal
Feed Enzymes and Products in the Field, including communications and interactions with Regulatory Authorities and, to the extent Novus (or its Subsidiary) files for registration in a given jurisdiction, Novus (and its Subsidiary, as applicable)
shall cooperate with Verenium to enable Verenium to manage such process in such jurisdiction. Both Parties will cooperate with the other to provide the information required to make and maintain filings for registration of the Animal Feed Enzymes and
Products in the Field, as necessary, in a timely fashion. In addition, the Party that is responsible for filing for registration shall provide the other Party with a copy of all material correspondence received from any Regulatory Authority or
provided to any Regulatory Authority with respect to Animal Feed Enzymes and Products in the Field, including minutes of all material communications with Regulatory Authorities, and shall provide the other Party with reasonable advance notice of all
material meetings, conferences, and discussions scheduled with Regulatory Authorities with respect to Animal Feed Enzymes and Products in the Field promptly after it receives notice of the scheduling of such meeting, conference, or discussion, and
such other Party shall be entitled to have reasonable representation present at all such meetings, conferences, or discussions and shall be able to participate in such meetings, 

  
 10 

 
conferences, or discussions as an observer (in each case to the extent permitted by the relevant Regulatory Authority). 
 (f) Permitted Affiliates and Third Parties. Either Party may have certain of the work allocated to the respective Parties in each Development Plan instead performed by an Affiliate or a Third Party
in accordance with the terms set forth herein so long as (i) any inventions or discoveries made by such Affiliate or Third Party during the course of performing such work shall be owned by the appropriate Party as set forth hereunder and
(ii) such work and any Confidential Information transferred during such work is subject to a confidentiality obligation no less restrictive in scope than the confidentiality obligations of the Parties hereunder. Each Party shall remain
responsible for the work to be performed by it, even if such work is performed by an Affiliate or Third Party. 
 (g)
Development Exclusivity. From the Effective Date until the earlier of [...***...] (the “Development Exclusivity Period”), each Party, [...***...] (the “Development Exclusivity Field”)
without prior written consent of the other Party. [...***...]. Nothing herein shall limit or restrict Verenium or its Affiliates or licensees from commercializing any Excluded Enzyme or product containing, incorporating or comprised of any
form of any Excluded Enzyme. In the event that a Party or its Affiliates, after the termination of the Development Exclusivity Period, works with or for any Third Party, independently of the other Party, to develop any [...***...] for use
within the Development Exclusivity Field (the “Other Project”), such Party agrees to (i) provide written notice to the other Party of an Other Project, (ii) reaffirm in writing the confidentiality obligations of Section 6.1,
(iii) be represented on Management Team under Section 2.5(b) by individuals that are not involved with the Other Project; and (iv) cooperate and take reasonable measures to ensure that the confidentiality obligations of the Parties
hereunder (including, without limitation, confidentiality of information discussed by and disclosed to the Management Team) will be respected and observed by the Parties. 
 (h) Scope of Activities. The Parties acknowledge that the development and regulatory activities contemplated by this Section 2.1 are intended to be conducted only in the Development
Exclusivity Field [...***...]. 

  

					
		  	11.	  	
		  		  	***Confidential Treatment Requested

 2.3 Manufacturing. 

(a) Determination of Manufacturer. Novus and Verenium shall determine, by mutual written agreement, whether Verenium, Novus or a
Third Party contract manufacturer reasonably acceptable to both Parties (or a combination thereof) will be responsible for manufacture of Animal Feed Enzymes and Products for commercial use in the Field. Determination of manufacturer pursuant to
this Section 2.3 shall take into account capabilities, existing manufacturing relationships, and ability to manufacture the Animal Feed Enzyme and Product at a competitive price and in compliance with the relevant industry standards and other
commercially reasonable requirements including, without limitation, requirements regarding quality assurance and control, total cost and capacity requirements. Within a timeframe mutually agreed to by the Parties, the Parties shall negotiate in good
faith and agree to an acceptable supply cost per kilogram range for each Animal Feed Enzyme and choose a potential manufacturing site. The Parties shall also agree on certain manufacturing targets that come into effect once production of Animal Feed
Enzymes and Products for commercial sale in the Field begins, which targets will be reflected in any supply agreement entered into with any manufacturer of Animal Feed Enzymes and Products for commercial use in the Field. The Parties acknowledge
that Verenium has existing manufacturing assets and a toll manufacturing relationship allowing for manufacture [...***...], which Novus agrees to evaluate as preferred initial manufacturing locations for Animal Feed Enzymes and Products.
[...***...]. If the Parties have discussed the selection of a manufacturer pursuant to this Section 2.3 but have not selected a manufacturer by mutual written agreement, a Party may provide written notice to the other Party of the
proposed selection of a manufacturer and, if the other Party does not provide written notice to the proposing Party of such other Party’s agreement or disagreement with such designation within [...***...] after receipt of such notice from
the proposing Party, then the proposing Party shall have final decision-making authority with respect to selection of such manufacturer. 
 (b) Verenium Assistance. In the event that a manufacturer other than Verenium or its current Third Party contract manufacturer is selected as the manufacturer of any Animal Feed Enzyme or Product
pursuant to Section 2.3(a), subject to the terms of the manufacture and supply agreement between Verenium and such manufacturer, Verenium shall grant, and hereby grants, to such manufacturer such license under the Verenium Manufacturing IP, on
a royalty-free basis (unless a royalty is required under any Third Party agreement pursuant to which Verenium has licensed such Verenium Manufacturing IP), and shall provide such Verenium Manufacturing IP to such manufacturer, in each case as
reasonably required for such manufacturer to manufacture such Animal Feed Enzyme or Product in the Field; provided that such manufacturer is subject to a confidentiality obligation to Verenium with respect to the

  

					
		  	12.	  	
		  		  	***Confidential Treatment Requested

 
Verenium Manufacturing IP no less restrictive in scope than the confidentiality obligations to Verenium hereunder and is required to assign ownership of any improvements to Verenium Manufacturing
IP to Verenium; and provided further that Verenium shall not license or provide any Verenium Manufacturing IP that has been licensed from any Third Party to the extent Verenium is not permitted to do so under any agreement with such Third Party.
Verenium agrees to provide reasonable assistance to such manufacturer to facilitate the understanding of the Verenium Manufacturing IP for purposes of manufacturing Animal Feed Enzymes and Products in the Field. Verenium shall be entitled to payment
for such assistance at a reasonable FTE rate to be agreed upon by the Parties, which shall be included in Development Costs under this Agreement. Notwithstanding other provisions herein to the contrary, nothing in this Agreement shall obligate
Verenium to provide to Novus or to any Third Party manufacturer information related to Verenium’s expression systems or fermentation development. 
 (c) Novus Assistance. In the event that a manufacturer of Animal Feed Enzymes other than Novus is selected as the manufacturer of any Animal Feed Enzyme or Product pursuant to Section 2.3(a),
subject to the terms of the manufacture and supply agreement between Novus and such manufacturer, Novus shall grant, and hereby grants, to such manufacturer, such license under the Novus Manufacturing IP, on a royalty-free basis (unless a royalty is
required under any Third Party agreement pursuant to which Verenium has licensed such Verenium Manufacturing IP), and shall provide such Novus Manufacturing IP to such manufacturer, in each case as reasonably required for such manufacturer to
manufacture such Animal Feed Enzyme or Product in the Field; provided that such manufacturer is subject to a confidentiality obligation to Novus with respect to the Novus Manufacturing IP no less restrictive in scope than the confidentiality
obligations to Novus hereunder and is required to assign ownership of any improvements to Novus Manufacturing IP to Novus; and provided further that Novus shall not license or provide any Novus Manufacturing IP that has been licensed from any Third
Party to the extent Novus is not permitted to do so under any agreement with such Third Party. Novus agrees to provide reasonable assistance to such manufacturer to facilitate the understanding of the Novus Manufacturing IP for purposes of
manufacturing Animal Feed Enzymes and Products in the Field. Novus shall be entitled to payment for such assistance at a reasonable FTE rate to be agreed upon by the Parties, which shall be included in Development Costs under this Agreement.

 2.4 Commercialization. 
 (a) Commercialization Activities. Subject to the terms and conditions of this Agreement, Novus shall be responsible for commercialization of Products in the Field. Novus shall conduct all such
commercialization activities in compliance, in all material respects, with all requirements of applicable laws. Novus shall regularly consult with and provide updates to Verenium regarding the commercialization strategy and the commercialization of
Products in the Field. Novus shall consider in good faith Verenium’s input regarding such commercialization strategy and commercialization activities; provided, however, that Novus shall have final decision-making authority with respect to
commercialization of Products in the Field, including the right to set the terms of sales and book all sales of Products in the Field in the Territory. 

  
 13 

 (b) Commercialization Plan. Novus shall be responsible for the creation and
implementation of a plan and budget for the commercialization of each Product in the Field (as may be amended by written agreement of the Parties, the “Commercialization Plan”). Each Commercialization Plan will include an
annual budget with key performance parameters and estimated costs and sales targets, which annual budget will be updated quarterly to reflect changes in required activity levels (as may be amended by written agreement of the Parties, the
“Annual Commercialization Budget”). Novus shall prepare and submit to Verenium the initial draft Commercialization Plan no later than [...***...] the earliest anticipated date of first commercialization of the first
Product in the Field for review and discussion. Novus shall thereafter submit a Commercialization Plan for any other Product at least [...***...] the earliest anticipated date of first commercialization of such Product in the Field. Any
updates to Commercialization Plans (including any change to any Annual Commercialization Budget) shall be submitted by Novus to Verenium for review and discussion. Each Commercialization Plan (including any Annual Commercialization Budget) and any
amendment thereto shall require the written approval of both Novus and Verenium. 
 (c) Diligence. During the Term, Novus
shall use commercially reasonable efforts to market, promote and commercialize Products in the Field in accordance with the Commercialization Plan and the terms of this Agreement. Without limiting the foregoing, Novus shall meet targets for minimum
annual sales of Products in the Field (the “Sales Targets”), such Sales Targets to be mutually agreed to by the Parties and set forth in the Commercialization Plan. If Novus believes in good faith that it will not be able to
achieve the Sales Targets for a given year for reasons outside of Novus’ reasonable control, it will provide written notice to Verenium summarizing the reasons for such belief and the annual sales of Products in the Field expected for such
year. The Parties will discuss such matter and make any amendment to or waiver of such Sales Targets for such year as agreed in writing by the Parties. The achievement or failure by Novus to reach the Sales Targets shall reasonably be taken into
account in determining whether Novus has used commercially reasonable efforts to market, promote and commercialize Products in the Field in accordance with the Commercialization Plan and the terms of this Agreement. [...***...]. 

(d) Branding. The Parties envision that the Animal Feed Enzymes will be commercialized under a new brand with Novus identified as
the primary marketer and Verenium identified as a technology provider. Novus and Verenium would own their respective brands and co-own the Joint Brand. The Parties agree that neither Party shall acquire or otherwise have any rights to the names,
brands or marks of the other Party with the exception of the rights to the Joint Brand set forth in this Agreement. Neither Party will do or cause to be done any act or thing contesting or, in any way, impairing the co-ownership by the Parties of
the Joint Brand. The nature and quality of Products produced, promoted, marketed and sold by either Party and its Subsidiaries on which the Joint Brand appears shall conform to quality standards and Product specifications for packaging and quality
control of Products reflected in applicable laws and regulatory approvals. In all packaging, labeling, advertising, promotional and other material referencing the Joint Brand, Novus and its Subsidiaries shall use the Joint Brand according to uses
approved by the Management Team, without varying the spelling or presentation, and 

  

					
		  	14.	  	
		  		  	***Confidential Treatment Requested

 
without modifying the design, including, without limitation, any colors or proportion of the Joint Brand. Novus will review and discuss with the Management Team any proposed Joint Brand and any
proposed modification or change thereto, and the adoption of any such Joint Brand and modification or change thereto shall be made only with Management Team approval, unless required by applicable law. Novus shall provide from time to time copies of
packaging, labeling, advertising, promotional and other material of Novus and its Subsidiaries referencing the Joint Brand to the Management Team to allow confirmation of compliance with the foregoing. Any accretion of goodwill derived by Novus and
its Subsidiaries to the extent attributed to the Joint Brand shall accrue to both Novus and Verenium as co-owners of the Joint Brand. 
 2.5 Governance. 
 (a) Establishment of Management Team. Novus and
Verenium hereby agree to establish the Management Team. The Management Team will act on behalf of the Parties and will be responsible for the planning and monitoring the activities of the Parties contemplated by this Agreement, including, without
limitation, (i) review and oversight of selection of Candidate Enzymes as Animal Feed Enzymes pursuant to the Candidate Selection Process, (ii) review and oversight of development and regulatory activities pursuant to the Development
Plans, and (iii) review and oversight of commercialization activities pursuant to the Commercialization Plans. The Management Team’s general directives, process for actions, and overall goals have been separately agreed to by the Parties
as of the Effective Date and may be amended by written agreement of the Parties. 
 (b) Management Team Membership. The
Management Team shall consist of four individuals with appropriate expertise as follows: (i) one dedicated individual from each Party to serve as project coordinator; and (ii) one individual from each Party to serve as that Party’s
managing director of the activities contemplated by this Agreement, with each such Management Team member appointed by Novus or Verenium, as applicable, in its sole discretion. Substitutes or alternates for Management Team members, if any, may be
appointed by the applicable Party at any time by written notice to the other Party. Novus and Verenium shall each bear all expenses of their respective Management Team members related to their participation on the Management Team and attendance at
Management Team meetings. 
 (c) Meetings. The Management Team shall meet at least monthly, unless the Parties agree
otherwise, with at least one meeting per year in person at a mutually agreed location, and other meetings to be in person, by telephone or by videoconference. Other employees of each Party, in addition to the members of the Management Team, may
attend Management Team meetings as nonvoting observers at the invitation of either Party with the prior approval of the Management Team. The Management Team shall keep minutes of its meetings that record all decisions and all actions recommended or
taken. Draft minutes shall be reviewed by Management Team members and issued in final form only with approval of the Management Team. 
 (d) Decisions and Dispute Resolution. All matters submitted for approval of the Management Team shall require unanimous approval, with the Novus members of the Management Team collectively having
one vote, and the Verenium members of the Management Team collectively having one vote. In the event the Management Team is unable to reach 

  
 15 

 
agreement on any matter properly before it, the dispute resolution provisions of Article 10 shall apply. 
 (e) Withdrawal. At any time during the Term and for any reason, Verenium shall have the right to withdraw from participation in the Management Team upon written notice to Novus, which notice shall
be effective immediately upon receipt. Following the issuance of such notice and subject to this Section 2.5(e), Verenium’s Management Team members will not participate in any meetings of, or have any right to vote on decisions within the
authority of, the Management Team. If, at any time, following the issuance of such withdrawal notice, Verenium wishes to resume participation in the Management Team, Verenium shall notify Novus in writing and, thereafter, Verenium’s
representatives on the Management Team shall be entitled to attend any subsequent meeting of the Management Team and to participate in the activities of, and decision-making by, the Management Team as provided in this Section 2.5 as if such
notice had not been issued by Verenium; provided that Verenium may not exercise the right to resume participation in the Management Team more than once. 
 2.6 Confirmation Following Change of Control. In the event of a Change of Control of either Novus or Verenium, the Party that is the subject of such Change of Control (or its successor in interest
as applicable) shall remain subject to all of the terms and conditions of this Agreement applicable to such Party. Without limiting the foregoing, the Parties shall cooperate and take reasonable measures to ensure that the confidentiality
obligations of the Parties hereunder (including, without limitation, confidentiality of information discussed by and disclosed to the Management Team) will be respected and observed by the Parties (and the successor in interest of the Party that is
the subject of such Change of Control as applicable). 
 ARTICLE 3 

LICENSES 
 3.1 License Grant. Subject to the terms and conditions of this Agreement, on the Effective Date Verenium hereby grants to Novus (a) an exclusive (subject to
Section 3.2), worldwide, royalty-bearing license, with no right to sublicense except to Novus’s Subsidiaries, under the Verenium Technology, to use, offer for sale, sell, import and export the Animal Feed Enzymes in the Field to the extent
necessary to make, have made, use, offer for sale, sell, import and export any Product that contains, incorporates or comprises any form of such Animal Feed Enzyme in the Field, (b) a non-exclusive, worldwide, royalty-free (unless a royalty is
required under any Third Party agreement pursuant to which Verenium has licensed such Verenium Manufacturing IP) license, with no right to sublicense except to Novus’s Subsidiaries, under the Verenium Manufacturing IP, to make and have made the
Animal Feed Enzymes in the Field to the extent necessary to make, have made, use, offer for sale, sell, import and export any Product that contains, incorporates or comprises any form of such Animal Feed Enzyme in the Field; provided that Verenium
shall not license any Verenium Manufacturing IP that has been licensed from any Third Party to the extent Verenium is not permitted to do so under any agreement with such Third Party (the licenses granted in subsections (a) and (b),
collectively, the “License”), and (c) an exclusive license to use the Joint Brand in connection with the production, promotion, marketing and sale of any Product that contains, incorporates or comprises any form of such
Animal Feed Enzyme in the Field (the license granted in subsection (c), the “Joint Brand 

  
 16 

 
License”). Except as provided in the preceding sentence, Verenium shall retain all of its rights under the Verenium Technology, the Verenium Manufacturing IP and the Joint
Brand. Novus agrees that Novus and its Subsidiaries (i) shall not practice any Verenium Technology except as expressly granted under the License in accordance with the terms of this Agreement, (ii) shall not practice any Verenium
Manufacturing IP unless and until Novus or its Subsidiary, or a Third Party contract manufacturer to the extent Novus contracts with such Third Party contract manufacturer rather than Verenium, is selected as a manufacturer of an Animal Feed Enzyme
pursuant to Section 2.3(a) and has entered into a manufacture and supply agreement contemplating the terms described in Section 2.3 and except as expressly granted under the License in accordance with the terms of this Agreement, and
(iii) shall not practice the Joint Brand except as expressly granted under the Joint Brand License in accordance with the terms of this Agreement. [...***...]. Novus may have certain of the commercialization activities with respect to
Products performed by its Subsidiaries in accordance with the terms set forth herein; provided that Novus shall remain responsible for the operations of its Subsidiaries relating to the Animal Feed Enzymes and Products as if such operations were
carried out by Novus and any sublicense granted to such Subsidiaries shall be consistent with the terms set forth in this Agreement. In the event that the Parties determine that Novus or a Third Party (other than Verenium’s current Third Party
contract manufacturer) will be responsible for manufacture pursuant to Section 2.3, the Parties will enter into a manufacture and supply agreement contemplating the terms described in Section 2.3, including a license to Novus or such Third
Party under Verenium Manufacturing IP to manufacture Animal Feed Enzymes for use in Products in the Field as contemplated by Section 2.3(b). In the event that the Parties determine that Verenium or a Third Party will be responsible for
manufacture pursuant to Section 2.3, the Parties will enter into a manufacture and supply agreement contemplating the terms described in Section 2.3, including a license to Verenium or such Third Party under Novus Manufacturing IP to
manufacture Animal Feed Enzymes for use in Products in the Field as contemplated by Section 2.3(c). 
 3.2 Effect of Novus Change of Control. Upon (a) the closing of a Novus Change of Control, or (b) the closing of any [...***...] in which [...***...], unless Novus notifies
Verenium in writing that [...***...], or the Parties discuss and agree in writing to include [...***...] and other terms of this Agreement, (i) [...***...] 

  

					
		  	17.	  	
		  		  	***Confidential Treatment Requested

 [...***...], and (ii) Novus hereby grants to Verenium, effective upon such closing, a
[...***...]. In the case of an event described in this Section 3.2, [...***...] may have certain [...***...] in accordance with the terms set forth herein; provided that [...***...] shall be consistent with the terms set
forth in this Agreement. 
 3.3 Limited Use of the Animal Feed Enzymes. Without Verenium’s express written consent,
Novus agrees not to modify the Animal Feed Enzymes in any way, reverse engineer the Animal Feed Enzymes, offer the Animal Feed Enzymes or any derivative thereof for resale (except as expressly set forth herein), file any patent applications based on
or otherwise disclosing the Animal Feed Enzymes or uses thereof, use the Animal Feed Enzymes outside the scope of the License, or use the Animal Feed Enzymes in any form of human or animal testing other than as contemplated by this Agreement. Except
as expressly set forth herein, Novus shall not transfer the Animal Feed Enzymes to any Third Party (provided that a successor in interest to Novus pursuant to an assignment of this Agreement in accordance with Section 11.4(a) shall be subject
to the terms applicable to Novus rather than being considered a Third Party), except that Novus may transfer the Animal Feed Enzymes to any Subsidiary of Novus; provided, however, that (a) Novus so notifies Verenium promptly thereafter; and
(b) each such transferee of the Animal Feed Enzymes (i) agrees not to modify any Animal Feed Enzyme in any way, reverse engineer any Animal Feed Enzyme, offer any Animal Feed Enzyme or any derivative thereof for resale (except as expressly
set forth herein), or use any Animal Feed Enzymes in any form of human or animal testing (except as expressly set forth herein), (ii) agrees, in the case of its use of any Animal Feed Enzyme in violation of clause (i) of this sentence or
outside the scope of the License, to assign ownership of all inventions made or discovered using such Animal Feed Enzyme in a manner consistent with the provisions set forth in this Agreement, and (iii) is subject to obligations of
confidentiality substantially similar to those set forth in Article 6 and to ownership of Inventions in accordance with Section 5.2. 
 3.4 Non-Assertion. During the term of development and regulatory activities under the Development Plans and solely for the purposes of carrying out the development and regulatory
activities as set forth in the Development Plans, (a) Verenium shall not bring against Novus any claims of infringement or misappropriation of Verenium Technology with respect to Novus’ development and regulatory activities with respect to
Animal Feed Enzymes in the Field in accordance with this Agreement, except for claims covered by Article 8, and (b) Novus shall not bring against Verenium any claims of infringement or misappropriation of Novus

  

					
		  	18.	  	
		  		  	***Confidential Treatment Requested

 
Technology with respect to Verenium’s development and regulatory activities with respect to Animal Feed Enzymes in the Field in accordance with this Agreement, except for claims covered by
Article 8, in each case solely for the purposes of carrying out development and regulatory activities with respect to Animal Feed Enzymes in the Field in accordance with this Agreement. The provisions of this Section 3.4 are intended to permit
both Parties to have freedom to carry out their respective development and regulatory activities with respect to Animal Feed Enzymes in the Field in accordance with this Agreement without fear of being made a party to any legal action concerning
infringing any intellectual property of the other Party that is used to carry out such activities. 
 3.5 No Implied
Licenses. No right or license under any Patent Rights or Know-How of either Party is granted or shall be granted by implication. All such rights or licenses are or shall be granted only as expressly provided in the terms of this Agreement.

 ARTICLE 4 
 PAYMENTS; RECORDS; AUDITS 

4.1 License Fees. In consideration of the rights and licenses granted to Novus under this Agreement, Novus agrees to pay to
Verenium a license fee of US$5,000,000 on the following schedule: 
 (a) Initial License Fee. Upon the Effective Date,
Novus shall pay to Verenium a non-refundable license fee of US$2,500,000 in consideration of the rights and licenses granted to Novus herein. 
 (b) [...***...] License Fee Payment. In addition, upon the earlier of [...***...], Novus shall pay Verenium a non-refundable license fee payment of US$2,500,000. 

The Parties agree that in no event shall Novus’s amortization of any of the license fee payments under this Section 4.1 be
included in Development Costs or in the calculation of Profits/Losses. 
 4.2 Development Costs. 

(a) Sharing of Development Costs. The Parties shall share equally (50%/50%) the Development Costs for Animal Feed Enzymes for
a given calendar quarter within the then-current Annual Development Budget or a variance of up to not more than 10% (or such greater variance as approved by the Management Team in writing). If a Party incurs Development Costs for a given calendar
quarter that exceed the then-current Annual Development Budget by more than 10% (or such greater variance as approved by the Management Team in writing), such Party shall be responsible for such excess Development Costs. 

  

					
		  	19.	  	
		  		  	***Confidential Treatment Requested

 (b) Payments. Development Costs shall initially be borne by the Party incurring them,
subject to reimbursement as provided herein. Each Party shall calculate and maintain records of Development Costs incurred by it in accordance with procedures to be established by the Management Team. Each Party shall report to the other Party on
Development Costs incurred each calendar quarter, with such reports to be submitted within 20 days after the end of each calendar quarter. The Parties shall seek to resolve any questions related to such accounting statements promptly (and in any
event within 10 days) following receipt. Within 15 days after receipt of the reports for each calendar quarter, Verenium shall provide Novus a written report based upon the reports provided by each Party, which sets forth the amount payable by Novus
to Verenium or Verenium to Novus, as applicable, so that the Parties share the Development Costs in accordance with Section 4.2(a). The Party that owes any amount to the other Party based upon such report provided by Verenium shall pay such
other Party the amount due within 20 days after the date of such report. 
 4.3 Profits/Losses. 

(a) Sharing of Profits/Losses. Commencing upon first commercial sale of a Product in a given jurisdiction, each Party shall share
equally (50%/50%) the Profit/Loss with respect to such Product, subject to the provisions of this Section 4.3. 

(b) Reporting. The reporting and determination of Profit/Loss shall be governed by a Profit/Loss statement to be prepared by Novus
and submitted to Verenium in substantially the form agreed to in writing by the Parties as of the Effective Date, as may be amended by written approval of the Management Team (the “Profit/Loss Statement”). The Profit/Loss
Statement shall include for each calendar quarter the Net Sales of Products and the Shared Expenses; provided that the total actual amount of Shared Expenses for the year to date have not exceeded the amounts budgeted for Shared Expenses for such
year within the then-current Annual Commercialization Budget by more than 10% (or such greater variance as approved by the Management Team in writing) for the year to date. If a Party incurs Shared Expenses that exceed the then-current Annual
Commercialization Budget for Shared Expenses for such year by more than 10% (or such greater variance as may be approved by the Management Team in writing), such Party shall be responsible for such excess Shared Expenses. 

(c) Payment. Novus shall determine and allocate Profit/Loss according to the Profit/Loss Statement and this Section 4.3 and
deliver to Verenium (i) the Profit/Loss Statement for the calendar quarters ending June 30, September 30 and December 31 within 30 days following the end of each such calendar quarter and (ii) an estimate of the Profit/Loss
Statement for the calendar quarter ending March 31 within thirty (30) days following the end of such calendar quarter and an actual Profit/Loss Statement within forty-five (45) days following the end of such calendar quarter. If, for
a given quarter there is a positive Profit/Loss amount (i.e., if Net Sales exceed Shared Expenses in accordance with Section 4.3(b) for such calendar quarter), Novus shall make a reconciling payment to Verenium concurrently with delivery of the
Profit/Loss Statement. In no event will Verenium be required to make any payment to Novus to the extent that, for a given quarter, there is a negative Profit/Loss amount (i.e., if Shared Expenses in accordance with Section 4.3(b) exceed Net
Sales for such calendar quarter), but instead the amount of Verenium’s 50% share of such Profit/Loss for such quarter (the “Credit Amount”) shall be treated as a credit to Novus and applied to reduce any future
payment(s) to 

  
 20 

 
Verenium under this Section 4.3(c) by such Credit Amount plus simple interest on such Credit Amount, net of tax savings to Novus for such Credit Amount, from the time incurred at a rate per
annum equal to the then-current prime rate established by CitiBank, as published in The Wall Street Journal. 
 4.4 Payment
to Designated Account. All payments due under this Agreement shall be payable in United States dollars. Each Party shall make all payments to the other Party by bank wire transfer in immediately available funds to an account designated in
writing by the Party to whom such payment is due. 
 4.5 Conversion. All amounts payable under this Section will first be
calculated in the currency of sale and then converted into United States dollars. The buying rates involved for the currency of the United States into which the currencies involved are being exchanged shall be consistent with the Accounting
Standards and Novus’s currency translation policy as used by Novus for its financial statements. Novus shall provide such policy as in effect from time to time to Verenium, and Verenium shall have the right to review currency rates used by
Novus at any time. 
 4.6 Books and Records. Each Party agrees to keep (and cause its applicable Affiliates to keep)
proper records and books of account in accordance with Accounting Standards, showing the Development Costs and Shared Expenses incurred by such Party and its Affiliates, and the sales of Novus and its Affiliates upon which the calculation of
Profits/Losses are based, and all other information necessary for the accurate determination of payments to be made in accordance with this Agreement. Such records shall be maintained for at least five (5) years after the date of the applicable
payment to which such records relates. 
 4.7 Audit. 

(a) Audit Procedures and Timing. Upon the written request of Novus (with respect to Development Costs of Verenium) or Verenium
(with respect to Development Costs of Novus, Shared Expenses, sales of Novus and its Affiliates upon which the calculation of Profits/Losses are based, and all other information necessary for the accurate determination of payments to Verenium) (as
applicable, the “Requesting Party”), and not more than once in each calendar year, the other Party (the “Audited Party”) shall permit an independent certified public accounting firm of nationally
recognized standing selected by the Audited Party and reasonably acceptable to the Requesting Party to have access during normal business hours to such of the records of the Audited Party and its applicable Affiliates as may be reasonably necessary
to verify the accuracy of the payments due and costs incurred under this Agreement, including the reports of Profits/Losses under this Agreement, for any period ending not more than five years prior to the date of such request. The accounting firm
shall disclose to the Requesting Party only whether the payments due and costs incurred, including any payment reports (as applicable), are correct or incorrect and the specific details concerning any discrepancies. No other information shall be
provided to the Requesting Party without the prior consent of the Audited Party unless disclosure is required by law, regulation or judicial order. The Audited Party is entitled to require the accounting firm to execute a reasonable confidentiality
agreement prior to commencing any such audit. 

  
 21 

 (b) Payments. The fees charged by such accounting firm shall be paid by the
Requesting Party; provided, however, that if the audit uncovers an underpayment by the Audited Party that exceeds 5% of the total payment owed, then the fees of such accounting firm shall be paid by the Audited Party. Any underpayments or unpaid
amounts discovered by such audit or otherwise will be paid promptly by the Audited Party within thirty (30) days of the date the Requesting Party delivers to the Audited Party such accounting firm’s written report, or as otherwise agreed
upon by the Parties, plus interest calculated in accordance with Section 4.9. In the event of an overpayment by the Audited Party, the Audited Party shall be entitled to credit such overpayment against any subsequent payment due to the
Requesting Party under this Agreement. 
 4.8 Taxes. A Party receiving payment under this Agreement shall pay any and all
income or franchise taxes levied on account of royalties and other payments it receives hereunder. If laws or regulations require that taxes be withheld, the paying Party will deduct such taxes from the amount due to the Party to whom such payment
is due, pay such taxes to the proper tax authority, and send evidence of the obligation together with proof of payment to the Party to whom such payment is due promptly after making such payment. 

4.9 Late Payments. Payments not remitted or deposited by the due date shall bear interest to the extent permitted by applicable
law at the then-current prime rate plus 2% established by CitiBank, as published in The Wall Street Journal, calculated on the number of days such payment is delinquent. The payment of such interest shall not limit the Party entitled to receive such
payment from exercising any other rights it may have as a consequence of the lateness of any payment. 
 ARTICLE 5

 INTELLECTUAL PROPERTY RIGHTS 

5.1 Ownership of Existing Technology. Each Party acknowledges and agrees that, as between the Parties, Verenium is and shall
remain the sole and exclusive owner of all right, title, and interest in and to the Verenium Technology existing as of the Effective Date or arising outside the course of work performed pursuant to this Agreement and all Verenium Manufacturing IP
and Verenium Core Technology, and Novus is and shall remain the sole and exclusive owner of all right, title, and interest in and to the Novus Technology existing as of the Effective Date or arising outside the course of work performed pursuant to
this Agreement and all Novus Manufacturing IP. 
 5.2 Inventions. 

(a) Inventorship. Inventorship of inventions, discoveries, developments, and improvements, whether or not patentable, conceived of
and/or reduced to practice solely by employees or consultants of either Novus or Verenium, or jointly by employees and consultants of both Novus and Verenium, in the course of work performed pursuant to this Agreement during the Term (collectively,
the “Inventions”) shall be determined in accordance with United States patent laws (and the Management Team shall select one representative with expertise in United States patent laws on behalf of each of Novus and Verenium
to assist in such 

  
 22 

 
determination). Each Party shall promptly inform the other Party in writing of any Inventions. For clarity, any and all inventions, discoveries, developments, and improvements, whether or not
patentable, to the extent they specifically relate to Verenium Core Technology shall be the sole property of Verenium. 
 (b) Ownership of Improvements to [...***...]. Any Invention that either (i) is an enhancement, modification or improvement of any [...***...], whether conceived of and/or
reduced to practice solely by employees or consultants of either Novus or Verenium, or jointly by employees and consultants of both Novus and Verenium, or (ii) relates to any [...***...] and is conceived of and/or reduced to practice
solely by employees or consultants of either Novus or Verenium or jointly by employees and consultants of both Novus and Verenium, in either such case together with all intellectual property rights in and to such Invention [...***...], shall
be owned solely by Verenium; provided, however, that any Invention that is a [...***...] and is conceived of and/or reduced to practice solely by employees or consultants of either Novus or Verenium or jointly by employees and consultants of
both Novus and Verenium, in either such case together with all intellectual property rights in and to such Invention [...***...], shall be owned [...***...]. 
 (c) [...***...] Manufacturing IP. Any Invention that either (i) is an enhancement, modification or improvement of any [...***...] Manufacturing IP, whether conceived of
and/or reduced to practice solely by employees or consultants of either Novus or Verenium, or jointly by employees and consultants of both Novus and Verenium, or (ii) relates to the [...***...] and is conceived of and/or reduced to
practice solely by employees or consultants of Verenium, in either such case, together with all intellectual property rights in and to such Invention [...***...], shall be owned [...***...]. 

(d) Ownership of Improvements to [...***...]. Any Invention [...***...] that is an enhancement, modification or
improvement of any [...***...], whether conceived of and/or reduced to practice solely by employees or consultants of either Novus or Verenium, or jointly by employees and consultants of both Novus and Verenium, together with all intellectual
property rights in and to such Invention [...***...], shall be owned [...***...]. 
 (e)
[...***...] Manufacturing IP. Any Invention [...***...] that relates to [...***...] and is conceived of and/or reduced to practice solely by employees or consultants of Novus, together with all intellectual property
rights in and to such Invention [...***...], shall be owned [...***...]. 

  

					
		  	23.	  	
		  		  	***Confidential Treatment Requested

 (f) Other Inventions. All Inventions, together with all intellectual property rights
in and to such Inventions, other than the [...***...], shall be owned solely by Verenium if conceived of and/or reduced to practice solely by employees or consultants of Verenium, solely by Novus if conceived of and/or reduced to practice
solely by employees or consultants of Novus, or jointly by Verenium and Novus if conceived of and/or reduced to practice jointly by employees or consultants of Verenium and employees or consultants of Novus. Such Inventions, together with all
intellectual property rights in and to such Inventions, shall be included in [...***...]. Each Party shall be free (without requiring the consent of, or accounting for any sums to the other Party) to exploit and to grant licenses or other
rights under such jointly-owned Inventions and intellectual property rights in and to such jointly-owned Inventions, except to the extent that such jointly-owned Inventions and intellectual property rights in and to such jointly-owned Inventions are
exclusively licensed to the other Party pursuant to this Agreement. 
 (g) Assignment. Each Party hereby
assigns to the other Party such rights as it may acquire in Inventions and intellectual property rights in and to Inventions as may be necessary or appropriate to cause such Inventions and intellectual property rights in and to such Inventions to be
owned by the appropriate Party as provided in Section 5.2(a) through (e), or if assignment is not permitted by law, waives such rights as to the other Party or grants to the other Party an exclusive, fully-paid, perpetual, irrevocable,
worldwide license under such rights (with the right to sublicense) for any and all purposes. Each Party agrees to execute any assignment or other documents reasonably necessary to convey to the other Party any right, title or other interest to
Inventions and intellectual property rights in and to Inventions as necessary to effect the ownership of such Inventions and intellectual property rights in and to Inventions as provided in Section 5.2(a) through (f), and, upon request, will
assist the other Party in connection with the preparation and prosecution of any application for intellectual property rights relating to any Invention owned by such other Party pursuant hereto. [...***...]. 

5.3 Filing, Prosecution, and Maintenance of Patents and Joint Brand. 

(a) Responsibility. 
 (i) Verenium Rights. Verenium (or its licensor with respect to any Patent Rights licensed to Verenium by a Third Party or its licensee under Patent Rights licensed by Verenium to a Third Party)
shall be responsible, at its sole expense, for preparing, filing, prosecuting and maintaining any Patent Rights within the Verenium Patent Rights or Verenium Manufacturing IP (other than any such Patent Rights jointly owned by the Parties, which
shall be subject to Section 5.3(a)(iii)). In the event that Verenium determines not to file for any such Patent Rights within the Verenium Patent Rights or to abandon or cease prosecution or maintenance of any such Verenium Patent Rights,
Verenium shall provide reasonable prior written notice to Novus of such intention not to file or to abandon or cease prosecution or 

  

					
		  	24.	  	
		  		  	***Confidential Treatment Requested

 
maintenance (which notice shall, to the extent possible, be given no later than 30 days prior to the next deadline for any action that must be taken with respect to any such Verenium Patent
Rights in the relevant patent office or proceeding). In such case, subject to the rights of Verenium’s licensor with respect to any Patent Rights licensed to Verenium by a Third Party or its licensee sunder Patent Rights licensed by Verenium to
a Third Party, Novus may elect, upon written notice by Novus to Verenium, to cause Verenium to file such Verenium Patent Rights or to continue prosecution and/or maintenance of such Verenium Patent Rights, at Novus’s sole cost and expense and
in accordance with Novus’s instructions, and Verenium shall do so for as long as Novus continues to pay the costs and expenses of filing for, prosecuting and/or maintaining such Verenium Patent Rights. Novus shall reimburse Verenium for such
costs and expenses incurred by Verenium within 30 days from the date of invoice for such costs and expenses by Verenium. In the event that Novus desires to cease bearing the costs and expenses with respect to any such Verenium Patent Rights, Novus
shall provide prior written notice to Verenium of such intention. In such case, Verenium, at its sole discretion, may elect to continue preparing, filing, prosecuting and maintaining any such Verenium Patent Rights at its own expense. 

(ii) Novus Rights. Novus (or its licensor with respect to any Patent Rights licensed to Novus by a Third Party) shall be
responsible, at its sole expense, for preparing, filing, prosecuting and maintaining any Patent Rights within the Novus Patent Rights or Novus Manufacturing IP (other than any such Patent Rights jointly owned by the Parties, which shall be subject
to Section 5.3(a)(iii)). In the event that Novus determines not to file for any such Patent Rights within the Novus Patent Rights or to abandon or cease prosecution or maintenance of any such Novus Patent Rights, Novus shall provide reasonable
prior written notice to Verenium of such intention not to file or to abandon or cease prosecution or maintenance (which notice shall, to the extent possible, be given no later than 30 days prior to the next deadline for any action that must be taken
with respect to any such Novus Patent Rights in the relevant patent office or proceeding). In such case, subject to the rights of Novus’s licensor with respect to any Patent Rights licensed to Novus by a Third Party, Verenium may elect, upon
written notice by Verenium to Novus, to cause Novus to file such Novus Patent Rights or to continue prosecution and/or maintenance of such Novus Patent Rights, at Verenium’s sole cost and expense and in accordance with Verenium’s
instructions, and Novus shall do so for as long as Verenium continues to pay the costs and expenses of filing for, prosecuting and/or maintaining such Novus Patent Rights. Verenium shall reimburse Novus for such costs and expenses incurred by Novus
within 30 days from the date of invoice for such costs and expenses by Novus. In the event that Verenium desires to cease bearing the costs and expenses with respect to any such Novus Patent Rights, Verenium shall provide prior written notice to
Novus of such intention. In such case, Novus, at its sole discretion, may elect to continue preparing, filing, prosecuting and maintaining any such Novus Patent Rights at its own expense. 

(iii) Jointly Owned Patent Rights and the Joint Brand. Unless otherwise agreed in writing by the Parties, Verenium shall have the
first right, with costs and expenses to be shared equally between Verenium and Novus, to be responsible for preparing, filing, prosecuting and maintaining any Patent Rights jointly by the Parties (including, without

  
 25 

 
limitation, Patent Rights with respect to [...***...] and the Joint Brand, using a patent counsel selected by Verenium and reasonably acceptable to Novus. Novus shall reimburse Verenium for
Novus’ portion of such costs and expenses incurred by Verenium within thirty (30) days from the date of invoice for such costs and expenses by Verenium. In the event that either Party desires to cease sharing the costs and expenses with
respect to any Patent Rights owned jointly by the Parties or the Joint Brand, such Party shall provide prior written notice to the other Party of such intention. In such case, the other Party, at its sole discretion, may elect to continue preparing,
filing, prosecuting and maintaining any such Patent Rights or the Joint Brand at its own expense, and the Party desiring to cease sharing such costs and expenses shall execute such documents and perform such acts, at the Party’s expense, as may
be reasonably necessary to effect an assignment of the Party’s entire right, title, and interest in and to such Patent Rights or the Joint Brand to other Party. 
 (b) Reporting; Standby Right for Jointly Owned Patent Rights and Joint Brand. Each Party with responsibility for preparing, filing, prosecuting and maintaining any Patent Rights as described in
this Section 5.3 shall (i) consult with and keep the other Party informed of progress with regard to all material communications and events relating to the preparing, filing, prosecuting and maintaining of such Patent Rights,
(ii) provide the other Party a reasonable opportunity (to the extent practicable) to comment on any document that is planned to be filed with the relevant patent office, and (iii) reasonably consider the other Party’s input. In the
event that Verenium elects not to exercise its first right to prepare, file, prosecute, or maintain any jointly owned Patent Rights or the Joint Brand, Verenium shall provide reasonable prior written notice to Novus (which notice shall, to the
extent possible, be given no later than sixty (60) calendar days prior to the next deadline for any action that must be taken with respect to such Patent Rights in the relevant patent office). Following the receipt of such notice, Novus shall
have the right, but not the obligation, at its sole expense to prepare, file, prosecute, obtain and maintain such jointly owned Patent Rights or the Joint Brand, as applicable, and Verenium shall execute such documents and perform such acts, at
Verenium’s expense, as may be reasonably necessary to effect an assignment of Verenium’s entire right, title, and interest in and to its joint ownership interest in such Patent Rights or the Joint Brand, as applicable, to Novus.

 5.4 Infringement by Third Parties. 
 (a) Notice. In the event that either Verenium or Novus becomes aware of any infringement or threatened infringement by a Third Party of any Patent Rights that are subject to the prosecution,
maintenance or enforcement of the other Party under this Agreement or of the Joint Brand, it will notify the other Party in writing to that effect. Any such notice shall include evidence to support an allegation of infringement or threatened
infringement by such Third Party. 
 (b) Responsibility. 

(i) Verenium Patent Rights. Verenium (or its Third Party licensor with respect to any Verenium Patent Rights licensed to Verenium
by such Third Party or its Third Party licensee under Verenium Patent Rights licensed by Verenium to such Third Party) shall have the sole right (but not the obligation), as between Verenium and Novus, except as provided in this
Section 5.4(b)(i), to bring and control any action or proceeding with respect to 

  

					
		  	26.	  	
		  		  	***Confidential Treatment Requested

 
infringement of any Verenium Patent Right (other than any such Patent Rights jointly owned by the Parties, which shall be subject to Section 5.4(b)(iii)) worldwide, at its own expense and by
counsel of its own choice. During any time that Novus holds an exclusive license under the applicable Verenium Patent Right in the Field, Novus shall have the right, at its own expense, to be represented in any such action with respect to
infringement of any Verenium Patent Right in the Field by counsel of its own choice, and Verenium and its counsel will reasonably cooperate with Novus and its counsel in strategizing, preparing and presenting any such action or proceeding. In the
event that Verenium determines not to bring any action or proceeding with respect to infringement of any such Verenium Patent Rights in a given country, then to the extent that any such infringement could reasonably be expected to have a material
adverse effect on any Product being developed or commercialized in the Field in such country (a “Material Activity”) and neither Verenium’s Third Party licensor with respect to any Verenium Patent Rights licensed to
Verenium by such Third Party or its Third Party licensee under Verenium Patent Rights licensed by Verenium to such Third Party has any right to bring such action or proceeding, then Verenium and Novus shall discuss in good faith permitting Novus to
bring such action or proceeding with respect to the Material Activity, at its own expense. If Novus is permitted to bring such action, Verenium shall have the right, at its own expense, to be represented in any such action by counsel of its own
choice. 
 (ii) Novus Patent Rights. Novus (or its Third Party licensor with respect to any Novus Patent Rights licensed
to Novus by such Third Party) shall have the sole right (but not the obligation), as between Verenium and Novus, except as provided in this Section 5.4(b)(ii), to bring and control any action or proceeding with respect to infringement of any
Novus Patent Right (other than any such Patent Rights jointly owned by the Parties, which shall be subject to Section 5.4(b)(iii)) worldwide, at its own expense and by counsel of its own choice. Verenium shall have the right, at its own
expense, to be represented in any such action by counsel of its own choice, and Novus and its counsel will reasonably cooperate with Verenium and its counsel in strategizing, preparing and presenting any such action or proceeding. In the event that
Novus determines not to bring any action or proceeding with respect to infringement of any such Novus Patent Rights in a given country, then to the extent that any such infringement is a Material Activity and Novus’s Third Party licensor with
respect to any Novus Patent Rights licensed to Novus by such Third Party does not have any right to bring such action or proceeding, then Verenium and Novus shall discuss in good faith permitting Verenium to bring such action or proceeding with
respect to the Material Activity, at its own expense. If Verenium is permitted to bring such action, Novus shall have the right, at its own expense, to be represented in any such action by counsel of its own choice. 

(iii) Jointly Owned Patent Rights; Joint Brand. Novus shall have the first right (but not the obligation), as between Verenium
and Novus, to bring and control any action or proceeding with respect to infringement of any jointly owned Patent Rights (including, without limitation, Patent Rights with respect to [...***...] or the Joint Brand worldwide, at its own expense
and by counsel of its own choice, and Verenium shall have the right, at its own expense, to be represented in any such action by counsel of its own choice. In the event that Novus fails to bring an action or proceeding with respect to jointly owned
Patent Rights or the Joint Brand within a period of one hundred eighty (180) days after a request by Verenium to do so (but in any event no fewer than ten (10) days before the time limit, if any, set forth in the appropriate laws and
regulations for the filing of such actions), Verenium shall have 

  

					
		  	27.	  	
		  		  	***Confidential Treatment Requested

 
the right to bring and control any such action by counsel of its own choice, and Novus shall have the right to be represented in any such action by counsel of its own choice at its own expense.
If Verenium brings any such action or proceeding, Novus agrees to be joined as a party plaintiff and to give Verenium reasonable assistance and authority to file and prosecute the suit. 

(iv) Settlement. A settlement or consent judgment or other voluntary final disposition of a suit under this Section 5.4 may
be entered into by the Party that has the right to bring and control such suit, without the consent of the other Party; provided that such settlement, consent judgment or other disposition with respect to any Patent Rights does not admit the
invalidity or unenforceability of any such Patent Rights; and provided further, that any rights to continue the infringing activity in such settlement, consent judgment or other disposition shall be limited to the product or activity that was the
subject of the suit. 
 (c) Cooperation. In the event a Party brings an infringement action in accordance with this
Section 5.4, the other Party shall cooperate fully, including, if required to bring such action, the furnishing of a power of attorney or being named or joining as a party to such action. 

(d) Allocation of Awards. Except as otherwise agreed to by the Parties as part of a cost-sharing arrangement, any recovery or
damages realized as a result of such action or proceeding shall be used first to reimburse the Parties’ documented out-of-pocket legal expenses relating to the action or proceeding, and any remaining recovery or damages shall be retained by the
Party that brought or controlled the action or proceeding and, to the extent such recovery or damages relates to the Animal Feed Enzymes and/or Products in the Field (including, without limitation, lost sales or lost profits with respect to Products
in the Field) shall be deemed Net Sales and included in Profits/Losses. 
 5.5 Infringement of Third Party Rights.
Verenium and Novus shall promptly notify the other in writing of any allegation by a Third Party that the manufacture, use, sale or importation of any Animal Feed Enzyme or Product in the Field or the exercise of the rights granted to the other
Party hereunder infringes or may infringe the intellectual property rights of such Third Party. Novus shall have the sole right to control any defense of any such claim involving alleged infringement of Third Party intellectual property rights by
Novus’ activities at its own expense and by counsel of its own choice, and Verenium shall have the right, at its own expense, to be represented in any such action by counsel of its own choice. Verenium shall have the sole right to control any
defense of any such claim involving alleged infringement of Third Party intellectual property rights by Verenium’s activities at its own expense and by counsel of its own choice, and Novus shall have the right, at its own expense, to be
represented in any such action by counsel of its own choice. Neither Party shall have the right to settle any patent infringement litigation under this Section 5.5 in a manner that diminishes the rights of the other Party under this Agreement
without the prior written consent of such other Party. Verenium and Novus shall promptly notify the other in writing of any allegation by a Third Party that the manufacture, use, sale or importation of any Animal Feed Enzyme or Product outside the
Field infringes or may infringe the intellectual property rights of such Third Party. 

  
 28 

 ARTICLE 6 
 CONFIDENTIALITY 
 6.1 Confidentiality Obligations.
The Receiving Party agrees that, subject to disclosures permitted or contemplated by this Agreement, it shall: 
 (a)
Maintain all Confidential Information in strict confidence, except that the Receiving Party may disclose or permit the disclosure of any Confidential Information to its or its Affiliates’ contractors, consultants, agents, advisors,
directors, officers and employees who are obligated to maintain the confidential nature of such Confidential Information subject to confidentiality obligations no less restrictive in scope than the confidentiality obligations of the Parties
hereunder and who need to know such Confidential Information for the purposes set forth in this Agreement; 
 (b) Use all
Confidential Information solely for the purposes set forth in, or as permitted by, this Agreement; and 
 (c) Allow its
or its Affiliates’ contractors, consultants, agents, advisors, directors, officers and employees who are subject to a confidentiality obligation no less restrictive in scope than the confidentiality obligations of the Parties hereunder to
reproduce the Confidential Information only to the extent necessary to effect the purposes set forth in this Agreement, with all such reproductions being considered Confidential Information. 
 Each Party shall be responsible for any breaches of this Section 6.1 by any of its or its Affiliates’ contractors, consultants, agents, advisors, directors, officers and employees. 

6.2 Exceptions. The obligations of the Receiving Party under Section 6.1 above shall not apply to any specific Confidential
Information to the extent that the Receiving Party can demonstrate by competent proof that such Confidential Information: 

(a) Was generally known to the public or otherwise part of the public domain prior to the time of its disclosure under this
Agreement; 
 (b) Entered the public domain after the time of its disclosure under this Agreement through means other
than an unauthorized disclosure resulting from an act or omission by the Receiving Party’s or its Affiliates’, contractors, consultants, agents, advisors, directors, officers or employees; 

(c) Was already known to the Receiving Party, other than under an obligation of confidentiality, at the time of disclosure by the
Disclosing Party; 
 (d) Is or was disclosed to the Receiving Party at any time, whether prior to or after the time of
its disclosure under this Agreement, by a Third Party having no fiduciary relationship with the Disclosing Party and having no obligation of confidentiality to the Disclosing Party with respect to such Confidential Information; or 

  
 29 

 (e) Is developed by the Receiving Party without use of any Confidential Information
of the Disclosing Party. 
 6.3 Permitted Disclosure. Each Party shall be permitted to disclose Confidential Information
in the event that, and only to the extent that, such information is required to be disclosed to comply with applicable laws or regulations (such as disclosure to the United States Securities and Exchange Commission or the United States Environmental
Protection Agency) or the rules of any stock exchange upon which a Party’s securities are listed, or to comply with a court or administrative order, provided that the Disclosing Party receives prior written notice of such disclosure and the
Receiving Party takes all reasonable and lawful actions to obtain confidential treatment for such disclosure and, if possible, to minimize the extent of such disclosure. In addition, each Party may disclose the terms of this Agreement to lenders,
investment bankers, financial institutions or other Third Parties solely for purposes of due diligence investigations or financing the business operations of such Party either (a) upon the written consent of the other Party or (b) if the
disclosing Party obtains a signed confidentiality agreement with such Third Party with respect to such information, upon terms consistent with those set forth in this Article 6. 

6.4 Public Announcements. If acceptable to both Parties, the Parties shall issue a joint press release or separate press releases
upon the execution of this Agreement and other events under this Agreement as determined by the Parties; provided, however, that mutual agreement of the Parties shall not be needed as to disclosures required under Section 6.3. Except for the
information disclosed in any such press release, neither Party shall use the name of the other Party or reveal the existence of or terms of this Agreement in any publicity or advertising without the prior written approval of the other Party, except
that (a) either Party may use the text of a written statement approved in advance by both Parties without further approval, (b) either Party may use the other Party’s name and then-current logo on its website as well as in investor
presentations and other documents made available to investors only to accompany pictures or text that describe the general subject matters of this Agreement, and (c) either Party shall have the right to identify the other Party and to disclose
the terms of this Agreement as provided in Section 6.3. 
 6.5 Equitable Relief. Given the nature of the
Confidential Information and the competitive damage that would result to a Party upon unauthorized disclosure, use or transfer of its Confidential Information to any Third Party, the Parties agree that monetary damages may not be a sufficient remedy
for any breach of this Article 6. In addition to all other remedies, a Party shall be entitled to specific performance and injunctive and other equitable relief as a remedy for any breach or threatened breach of this Article 6. 

ARTICLE 7 

REPRESENTATIONS; WARRANTIES; DISCLAIMERS 

7.1 Organization; Good Standing. Each Party hereby represents to the other Party on the Effective Date that it: 

(a) is a corporation duly organized, validly existing, 

  
 30 

 (b) is in good standing under the laws of the jurisdiction of its incorporation,

 (c) is qualified to do business and in good standing in each jurisdiction in which the performance of its obligations
hereunder requires such qualification, and 
 (d) has all requisite power and authority, corporate or otherwise, and the
legal right to conduct its business as now being conducted, to own, lease and operate its properties and to execute, deliver and perform under this Agreement. 
 7.2 Binding Obligation; Due Authorization; No Conflict. Each Party hereby represents to the other Party on the Effective Date that this Agreement is a legal and valid obligation binding upon its
execution and enforceable in accordance with its terms and conditions. The execution, delivery, and performance of this Agreement by such Party have been duly authorized by all necessary corporate action, and the person executing this Agreement on
behalf of such Party has been duly authorized to do so by all requisite corporate actions and do not and will not (a) require any consent or approval of its stockholders or any Third Party or (b) conflict with, or constitute a material
breach or violation of, any agreement, instrument, understanding, oral or written, to which it is a party or by which it may be bound, and any judgment of any court or governmental body applicable to such a Party, or (c) violate any law,
decree, order, rule or regulation of any court, governmental body or administrative or other agency having authority over it. 

7.3 Additional Novus Representations and Warranties. Novus hereby represents to Verenium on the Effective Date that: 

(a) Title to Intellectual Property Rights. Novus has sufficient legal and beneficial title under its intellectual property rights
necessary for the purposes contemplated under this Agreement and to grant the licenses and rights contained in this Agreement without violating the terms of any agreement or other arrangements with any Third Party. 

7.4 Additional Verenium Representations and Warranties. Verenium hereby represents to Novus on the Effective Date that:

 (a) Title to Intellectual Property Rights. Verenium has sufficient legal and beneficial title under its intellectual
property rights, including the Verenium Patent Rights, necessary for the purposes contemplated under this Agreement and to grant the licenses and rights contained in this Agreement without violating the terms of any agreement or other arrangements
with any Third Party. Other than the Verenium Patent Rights and the Verenium Manufacturing IP, there are no Patent Rights owned or licensed by Verenium that are necessary for the manufacture, use, offer for sale, sale, import or export of Product in
the Field. 
 (b) No Legal Actions. Verenium does not have any knowledge of, and Verenium has not received written notice
of, any pending or threatened legal actions, judgments or settlements against or owed by Verenium with respect to the Verenium Technology or any Enzymes. 
 (c) No Proceedings. Verenium does not have any knowledge of, and Verenium has not received written notice of, the institution or threatened institution of any 

  
 31 

 
interference, reexamination, reissue, revocation or nullification involving any Verenium Patent Rights or other proceeding that challenges the inventorship, ownership, validity or enforceability
as applicable of any Verenium Patent Rights. 
 (d) Non-Infringement of Third Party Rights. Verenium does not have any
knowledge of, and Verenium has not received written notice of, any actual or threatened claim or assertion that the use or practice of the Verenium Technology infringes or misappropriates the intellectual property rights of a Third Party.

 (e) Non-Infringement by Third Parties. Verenium does not have any knowledge of, and Verenium has not received written
notice of, any use of any Candidate Enzyme in the Field that would constitute infringement or misappropriation of the Verenium Technology by Third Parties, except as disclosed in writing to Novus. 

7.5 Disclaimers. Each Party hereby acknowledges that the data and any materials provided or licensed hereunder are of an
experimental nature, provided without warranties, and neither Party shall accept any liability in connection with their use, storage and disposal by the other Party. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, NEITHER PARTY MAKES ANY
REPRESENTATION OR WARRANTY TO THE OTHER PARTY OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF NONINFRINGEMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR THAT ANY TECHNOLOGY WILL BE FREE FROM INFRINGEMENT OF PATENTS OR
PROPRIETARY RIGHTS OF THIRD PARTIES, OR THAT NO THIRD PARTIES ARE IN ANY WAY INFRINGING PATENT RIGHTS. WITHOUT LIMITING THE GENERALITY OF THE FOREGOING, EACH PARTY ACKNOWLEDGES THAT NO REPRESENTATION OR WARRANTY IS MADE REGARDING THE UTILITY OF ANY
INFORMATION, MATERIALS OR TECHNOLOGY LICENSED HEREUNDER. EACH PARTY EXPRESSLY DISCLAIMS ALL REPRESENTATIONS AND WARRANTIES AS TO THE VALIDITY OR SCOPE OF PATENTS AND PATENT CLAIMS, ISSUED AND PENDING, PROTECTING ITS TECHNOLOGY. 

ARTICLE 8 

INDEMNIFICATION 
 8.1 By Novus. Novus shall indemnify, defend, and hold harmless Verenium and its Affiliates and their directors, officers, employees and agents and their respective successors, heirs and assigns,
against any and all losses, liabilities, damages, penalties, fines, costs and expenses (including reasonable attorneys’ fees and other expenses of litigation) (“Losses”) incurred by any such indemnified party as a result
of any claims, actions, suits or proceedings brought by a Third Party (a “Third Party Claims”) arising from or relating to [...***...] any material breach of any representations, warranties or covenants by
Novus under this Agreement; except to the extent such Losses are directly attributable to the negligence or willful misconduct of Verenium or fall within the scope of the indemnification obligations of Verenium set forth in Section 8.2.

  

					
		  	32.	  	
		  		  	***Confidential Treatment Requested

 8.2 By Verenium. Verenium shall indemnify, defend, and hold harmless Novus and its
Affiliates and their directors, officers, employees and agents and their respective successors, heirs and assigns, against any and all Losses incurred by any such indemnified party as a result of any Third Party Claims arising from or relating to
[...***...] any material breach of any representations, warranties or covenants by Verenium under this Agreement; except to the extent such Losses are directly attributable to the negligence or willful misconduct of Novus or fall within
the scope of the indemnification obligations of Novus set forth in Section 8.1. 
 8.3 Procedures. Any party that
intends to claim indemnification under Section 8.1 or 8.2, as the case may be (an “Indemnitee”), shall promptly notify either Verenium or Novus, as applicable (the “Indemnitor”), of any Third
Party Claim in respect of which the Indemnitee intends to claim such indemnification, and the Indemnitor shall assume the defense thereof with counsel mutually satisfactory to the Parties; provided, however, that an Indemnitee shall have the right
to retain its own counsel at its own expense. Section 8.1 or 8.2, as the case may be, shall not apply to amounts paid in settlement of any loss, claim, liability or action if such settlement is effected without the consent of the Indemnitor.
Without prejudice to the provision contained in the previous sentence, the failure to deliver notice to the Indemnitor within a reasonable time after the commencement of any such action shall not relieve the Indemnitor of any liability to the
Indemnitee under Section 8.1 or 8.2, as the case may be, except to the extent the Indemnitor has been prejudiced by such failure to give notice. Each Party and its applicable Affiliates and their employees and agents shall cooperate fully with
the other Party and its legal representatives in the investigation of any action, claim or liability covered by this Article 8. 

8.4 Insurance. Each Party agrees to maintain a liability insurance program which is consistent with sound business practice and
reasonable in light of its obligations under this Agreement. 
 ARTICLE 9 

TERM; TERMINATION 
 9.1 Term. The term of is Agreement shall commence as of the Effective Date and shall continue for so long as the Parties are developing or commercializing any Animal Feed Enzymes or Products in the
Field, unless terminated earlier as provided herein (the “Term”). 
 9.2 Mutual Consent. This
Agreement may be terminated or extended at any time by mutual written agreement of the Parties. 
 9.3 Material Breach.

 (a) Notice of Breach. In the event of any breach or default of any material representation, warranty or obligation
under this Agreement by a Party, the non-breaching Party shall give the breaching Party written notice thereof, which notice must state the nature of the breach or default in reasonable detail and request that the breaching Party cure such breach or
default. 

  

					
		  	33	  	
		  		  	***Confidential Treatment Requested

 (b) Termination for Breach. Except for disputes as to payment (which disputes are
dealt with under Section 9.3(c)), the non-breaching Party may, in addition to any other remedies which may be available to such non-breaching Party at law or equity, terminate this Agreement in the event of a material breach or default that has
not been cured within 60 days after receipt of notice of such breach or default; provided that, if such breach or default is capable of being cured but cannot be cured within such 60-day period and the breaching Party initiates actions to cure such
breach within such period and thereafter diligently pursues such actions, the breaching Party shall have such additional period as is reasonable under the circumstances to cure such breach or default, but in no event more than an additional 60 days.

 (c) Breach of Payment Obligations. In the event that a Party fails to make timely payment of any amounts that are not
the subject of a good faith dispute regarding payment and that are due under this Agreement within 30 days after demand therefor, the other Party may terminate this Agreement upon 30 days prior written notice, unless such Party cures such breach by
paying all past-due amounts that are not the subject of a good-faith dispute between the Parties within such 30-day notice period. 
 9.4 Termination for Patent Challenges. Novus shall have the right to terminate this Agreement immediately upon written notice to Verenium if Verenium or any of its Affiliates directly, or
indirectly through any Third Party, commences any interference or opposition proceeding with respect to, challenges the validity or enforceability of, or opposes any extension of or the grant of a supplementary protection certificate with respect
to, any Patent Rights within the Novus Technology or the Novus Manufacturing IP. Verenium shall have the right to terminate this Agreement immediately upon written notice to Novus if Novus or any of its Affiliates directly, or indirectly through any
Third Party, commences any interference or opposition proceeding with respect to, challenges the validity or enforceability of, or opposes any extension of or the grant of a supplementary protection certificate with respect to, any Patent Rights
within the Verenium Technology, the Verenium Manufacturing IP or the Verenium Core Technology. 
 9.5 Limited Termination
Right. 
 (a) By Novus. Following the [...***...] of the Effective Date, Novus shall have the right to terminate
this Agreement in its entirety with [...***...] prior written notice to Verenium, such termination to be effective upon the [...***...] of such written notice of termination; provided that Verenium may, in its sole discretion,
[...***...]. Novus shall fulfill all of its obligations under this Agreement during such [...***...], including without limitation, its funding obligations under Section 4.2 pursuant to the Annual Development Budgets or extensions
thereof (for periods extending beyond the term of Annual Development Budgets), and there shall be no refund of any license payments or expenses paid by Novus. 
 (b) By Management Team [...***...]. Following the [...***...] of the Effective Date, the Management Team may agree in writing to terminate this Agreement as to a
[...***...], 

  

					
		  	34.	  	
		  		  	***Confidential Treatment Requested

 
in which case this Agreement shall be terminated as to [...***...] effective upon the date [...***...]. Each Party shall fulfill all of its obligations under this Agreement with
respect to [...***...] until any such termination date, including without limitation, funding obligations under Section 4.2 pursuant to the Annual Development Budgets or extensions thereof (for periods extending beyond the term of Annual
Development Budgets), and there shall be no refund of any license payments or expenses paid by Novus. 
 9.6 Bankruptcy.

 (a) Termination. A Party may terminate this Agreement if, during the Term, the other Party shall file in court or
agency pursuant to any statute or regulation of any state or country, a petition in bankruptcy or insolvency or for reorganization or for an arrangement or for the appointment of a receiver or trustee of the Party or of its assets, or if the other
Party proposes a written agreement of composition or extension of its debts, or if the other Party shall be served with an involuntary petition in bankruptcy or seeking reorganization, liquidation, dissolution, winding-up arrangement, composition or
readjustment of its debts or any other relief under any bankruptcy, insolvency, reorganization or other similar act or law of any jurisdiction now or hereafter in effect, or there shall have been issued a warrant of attachment, execution or similar
process against it, filed in any insolvency proceeding, and such petition shall not be dismissed within 90 days after the filing thereof, or if the other Party shall propose or be a Party to any dissolution or liquidation, or if the other Party
shall make an assignment for the benefit of creditors. 
 (b) Rights in Bankruptcy. 

(i) All rights and licenses granted under or pursuant to this Agreement, including without limitation, all rights and licenses to
use, improvements or enhancements developed during the term of this Agreement are intended to be, and shall be deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code, licenses of rights to “intellectual property” as
defined under Section 101 of the U.S. Bankruptcy Code. The Parties agree that each Party that is a licensee of such rights under this Agreement shall retain and may fully exercise its rights and elections under the U.S. Bankruptcy Code. The
Parties further agree that, in the event of the commencement of a bankruptcy proceeding by or against either Party under the U.S. Bankruptcy Code, the Party hereto which is not a Party to such proceeding shall be entitled to a complete duplicate of
(or complete access to, as appropriate) any such intellectual property and all embodiments of such intellectual property, and same, if not already in their possession, shall be, within 10 days of the commencement of such proceeding, delivered to
them (i) upon any such commencement of a bankruptcy proceeding upon their written request therefore, unless the Party subject to such proceeding (or a trustee on behalf of the subject Party) elects to continue to perform all of their
obligations under this Agreement or (ii) if not delivered under (i) above, upon the rejection of this Agreement by or on behalf of the Party subject to such proceeding upon written request therefore by the non-subject Party. 

(ii) In the event that this Agreement is deemed to be an “executory contract” for purposes of Section 365 of the
Bankruptcy Code, Section 365(n) thereof shall be implicated by any rejection or proposed rejection of this Agreement by either Party (the “Licensor”) in any bankruptcy proceeding, and the other Party (the 

  

					
		  	35.	  	
		  		  	***Confidential Treatment Requested

 
“Licensee”) shall have the right to retain and fully exercise all of its rights hereunder regardless of any such proceeding. All of the rights granted to Licensee under this Agreement
shall be deemed to exist immediately before the occurrence of any bankruptcy case in which Licensor is a debtor. Licensee shall retain and may fully exercise all of its rights and elections under the Bankruptcy Code or equivalent legislation in any
other jurisdiction. Without limiting the foregoing, Licensor acknowledges that the rights and licenses granted to Licensee pursuant to this Agreement shall not be affected by the rejection of this Agreement in bankruptcy, and shall continue subject
to the term and conditions of this Agreement. In the event that this Agreement is rejected or deemed rejected in a bankruptcy proceeding (a “Rejection”), the Licensor shall provide written notice thereof to Licensee in
accordance with Section 11.5. In the event that Licensee makes no election under Section 365(n) of the Bankruptcy Code within sixty (60) days following written notice of such Rejection to either treat the contract as terminated, or to
retain its rights, unless otherwise ordered by the court in any bankruptcy proceeding, (i) Licensee shall be deemed to have made a formal election to retain its rights under Section 365(n)(1)(B), to demand that the trustee in such
bankruptcy provide Licensee any intellectual property held by such trustee that is subject to the contract (including any embodiment of such intellectual property), and to not interfere with the rights of Licensee as provided in such contract, under
Section 365(n)(3)(A) of the Bankruptcy Code; and (ii) to the extent any rights of Licensee under this Agreement are determined by a bankruptcy court not to be “intellectual property rights” for purposes of Section 365(n) of
the Bankruptcy Code, all of such rights shall remain vested in and fully retained by Licensee after any such Rejection. Licensee shall under no circumstances be required to terminate this Agreement after Rejection in order to enjoy or acquire any of
its rights under this Agreement. 
 9.7 Disposition of Confidential Information. In the event of termination (in whole or
part) or expiration of this Agreement, the Parties shall return or destroy all Confidential Information of the other Party (or such Confidential Information of the other Party relating to the [...***...] in the case of termination of this
Agreement as to a [...***...] under Section 9.5(b)) within 30 days after such termination or expiration, provided, however, that each Party may retain one copy of such Confidential Information for record keeping purposes subject to a
continuing obligation of confidentiality under Article 7. 
 9.8 Effect of Termination or Expiration. 

(a) General. Upon termination of this Agreement in its entirety or expiration of this Agreement, all rights and obligations of the
Parties under this Agreement shall terminate except as provided in this Section 9.8. Upon termination of this Agreement as to a [...***...], all rights and obligations of the Parties under this Agreement shall terminate as to the
[...***...] except as provided in this Section 9.8, all Enzymes in the [...***...] shall not be considered Candidate Enzymes or Animal Feed Enzymes and Novus shall have no further rights hereunder with respect to such Enzymes, and
this Agreement shall remain in effect in accordance with its terms with respect to all categories of Enzymes other than the [...***...]. Termination (in whole or part) or expiration of this Agreement shall not relieve the Parties of any
obligation accruing prior to such termination or expiration. The provisions of Articles 1, 6, 8, 10 and 11 (excluding Section 11.1) and Sections 4.7, 5.1, 5.2, 7.5, 9.7 and 9.8 shall survive the expiration or termination (in whole or

  

					
		  	36.	  	
		  		  	***Confidential Treatment Requested

 
part) of this Agreement. Termination of this Agreement (in whole or part) shall not limit any other rights and remedies of the Parties. 

(b) Rights Upon Termination of Agreement by Novus under Section 9.5(a). If Novus terminates this Agreement pursuant to
Section 9.5(a), then, effective upon such termination: 
  

	 	(i)	Novus shall, and hereby does, grant to Verenium (A) [...***...] license, [...***...] under [...***...], and (B) a [...***...] license,
[...***...] under [...***...]; 

  

	 	(ii)	Novus shall, and hereby does, assign to Verenium [...***...] together with [...***...] or if assignment is not permitted by law, [...***...];

  

	 	(iii)	following notice of such termination, Novus shall make good faith efforts to assist Verenium with Verenium’s reasonable requests in connection with
[...***...], including, without limitation, [...***...]; and 

  

	 	(iv)	if and for so long as Verenium [...***...] with respect to [...***...] in connection with [...***...], Novus shall not, [...***...].

 (c) Rights Upon Termination of Agreement as to [...***...]. If this Agreement is terminated
as to [...***...] pursuant to Section 9.5(b), then, effective upon such termination: 
  

	 	(i)	Novus shall, and hereby does, grant to Verenium (A) [...***...] license, [...***...] under [...***...] and (B) a [...***...] license,
[...***...] under [...***...] 

  

					
		  	37.	  	
		  		  	***Confidential Treatment Requested

	 	        	[...***...]; 

  

	 	(ii)	Novus shall, and hereby does, assign to Verenium [...***...] together with all [...***...] or if assignment is not permitted by law,
[...***...]; 

  

	 	(iii)	following notice of such termination, Novus shall make good faith efforts to assist Verenium with Verenium’s reasonable requests in connection with
[...***...], including, without limitation, [...***...]; and 

  

	 	(iv)	if and for so long as Verenium [...***...] with respect to [...***...] in connection with [...***...] Novus shall not, [...***...].

 (d) Rights Upon Termination of Agreement by Verenium. In addition, if Verenium terminates this Agreement
pursuant to Section 9.3, 9.4, 9.6(a) or 11.2, then, effective upon such termination: 
  

	 	(i)	Novus shall, and hereby does, grant to Verenium (A) [...***...] license, [...***...] under [...***...] and (B) a [...***...] license,
[...***...] under [...***...]; and 

  

	 	(ii)	if and for so long as Verenium [...***...] with respect to [...***...] in connection with [...***...] Novus shall not, [...***...].

 ARTICLE 10 
 DISPUTE RESOLUTION 
 10.1 Disputes.
The Parties recognize that disputes as to certain matters arising under or relating to this Agreement or either Party’s rights and/or obligations hereunder may arise from 

  

					
		  	38.	  	
		  		  	***Confidential Treatment Requested

 
time to time. It is the objective of the Parties to establish procedures to facilitate the resolution of such disputes in an expedient manner by mutual cooperation and without resort to
litigation. To accomplish this objective, the Parties agree to follow the procedures set forth in Section 10.2 if and when such a dispute arises between the Parties. 
 10.2 Procedures. The Parties shall attempt in good faith to resolve any dispute arising out of or relating to this Agreement promptly by negotiation between executives who have the authority to
settle the controversy. Either Party may give the other Party written notice of a dispute not resolved in the normal course of business. If the matter has not been resolved by such executives within 60 days of a disputing Party’s notice, the
Parties agree to submit the matter to mediation unless mediation is waived upon written consent of the Parties. If the matter is submitted to mediation but is not resolved through negotiation or mediation, or if the Parties waive mediation, either
Party may initiate binding arbitration as provided in Section 10.3. 
 10.3 Arbitration. Arbitration of disputes or
claims (each, a “Claim”) between the parties under this Section 10.3 shall be administered by JAMS in accordance with its Comprehensive Arbitration Rules and Procedures. The arbitration shall be held in San Francisco,
California. The arbitration shall be conducted by one arbitrator who is knowledgeable in the subject matter at issue in the dispute. The arbitrator will be selected by written agreement of the Parties. The arbitrator shall, within 15 days after the
conclusion of the arbitration hearing, issue a written award and statement of decision describing the essential findings and conclusions on which the award is based, including the calculation of any damages awarded. The arbitrator shall be
authorized to award compensatory damages, but shall NOT be authorized (a) to award non-economic damages, such as for emotional distress, pain and suffering or loss of consortium, (b) to award punitive or multiple damages, or (c) to
reform, modify or materially change this Agreement or any other agreements contemplated hereunder; provided, however, that the damage limitations described in subsections (a) and (b) of this sentence will not apply if such damages are
statutorily imposed. The arbitrator also shall be authorized to grant any temporary, preliminary or permanent equitable remedy or relief the arbitrator deems just and equitable and within the scope of this Agreement, including, without limitation,
an injunction or order for specific performance. The decision of the arbitrator shall be final and binding upon the Parties. The award of the arbitrator shall be the sole and exclusive remedy of the Parties. Judgment on the award rendered by the
arbitrator may be entered in any court having competent jurisdiction thereof. This Section 10.3 shall not apply to any dispute, controversy or claim that concerns (i) the validity or infringement of a patent, trademark or copyright; or
(ii) any antitrust, antimonopoly or competition law or regulation, whether or not statutory. Notwithstanding the foregoing, claims for injunctive relief shall not be subject to the requirements of arbitration. 

10.4 Costs and Awards. Each Party shall bear its own attorneys’ fees, costs, and disbursements arising out of the
arbitration, and shall pay an equal share of the fees and costs of the arbitrator; provided, however, that the arbitrator shall be authorized to determine whether a Party is the prevailing Party, and if so, to award to that prevailing Party
reimbursement for its reasonable attorneys’ fees, costs and disbursements (including, for example, expert witness fees and expenses, photocopy charges, and travel expenses), and/or the fees and costs of the arbitrator.

  
 39 

 10.5 Waiver and Acknowledgement. By agreeing to this binding arbitration provision,
the Parties understand that they are waiving certain rights and protections which may otherwise be available if a Claim between the Parties were determined by litigation in court, including, without limitation, the right to seek or obtain certain
types of damages precluded by this provision, the right to a jury trial, certain rights of appeal, and a right to invoke formal rules of procedure and evidence. 
 ARTICLE 11 
 MISCELLANEOUS 

11.1 Standstill Agreement. During the Term (the “Standstill Period”), neither Novus nor any of
Novus’s Representatives (as defined below) will, in any manner, directly or indirectly: 
 (a) make, effect,
initiate, directly participate in or cause (i) any acquisition of beneficial ownership of any securities of Verenium or any securities of any subsidiary or other Affiliate of Verenium, if, after such acquisition, Novus would beneficially own
more than 5% of the outstanding common stock of Verenium, (ii) any acquisition of any assets of Verenium or any assets of any subsidiary or other Affiliate of Verenium, (iii) any tender offer, exchange offer, merger, business combination,
recapitalization, restructuring, liquidation, dissolution or extraordinary transaction involving Verenium or any subsidiary or other Affiliate of Verenium, or involving any securities or assets of Verenium or any securities or assets of any
subsidiary or other affiliate of Verenium, or (iv) any “solicitation” of “proxies” (as those terms are used in the proxy rules of the Securities and Exchange Commission) or consents with respect
to any securities of Verenium provided that nothing in this Section 11.1 shall preclude any activities of Novus or its Representatives with respect to the grant by Verenium or any Affiliate of Verenium of any license, or the supply by Verenium
or any subsidiary or other Affiliate of Verenium of any products, in each case to Novus or any of its Affiliates as contemplated by this Agreement; 
 (b) form, join or participate in a group (within the meaning of Section 13(d)(3) of the Securities Exchange Act of 1934, as amended) with respect to the beneficial ownership of any securities
of Verenium; 
 (c) act, alone or in concert with others, to seek to control the management, board of directors or
policies of Verenium; 
 (d) take any action that might require Verenium to make a public announcement regarding any of
the types of matters set forth in Section 11.1(a); 
 (e) agree or offer to take, or encourage or propose (publicly
or otherwise) the taking of, any action referred to in Section 11.1(a), (b), (c) or (d); 
 (f) assist, induce
or encourage any Third Party to take any action of the type referred to in Section 11.1(a), (b), (c), (d) or (e); 

(g) enter into any discussions, negotiations, arrangement or agreement with any Third Party relating to any of the foregoing; or

  
 40 

 (h) request or propose that Verenium or any of Verenium’s Representatives amend,
waive or consider the amendment or waiver of any provision set forth in this Section 11.1. 
 For purposes of this
Agreement, a Verenium’s “Representatives” will be deemed to include each person or entity that is or becomes (i) an Affiliate of Verenium, or (ii) an officer, director, employee, partner, attorney, advisor,
accountant, agent or representative of Verenium or of any of Verenium’s Affiliates, providing such person is acting on behalf of such Verenium. For purposes of this Agreement, Novus’s “Representatives” will be
deemed to include each person or entity that is or becomes (i) a Subsidiary of Novus, or (ii) an officer, director, employee, partner, attorney, advisor, accountant, agent or representative of Novus or of any of Novus’s Affiliates,
providing such person is acting on behalf of Novus. 
 The expiration of the Standstill Period will not terminate or otherwise
affect any of the other provisions of this Agreement. 
 11.2 Force Majeure. Neither Party shall be held liable or
responsible to the other Party nor be deemed to have defaulted under or breached this Agreement for failure or delay in fulfilling or performing any term of this Agreement (other than non-payment) when such failure or delay is caused by or results
from causes beyond the reasonable control of the affected Party, including, without limitation, fire, floods, earthquakes, natural disasters, embargoes, war, acts of war (whether war be declared or not), insurrections, riots, civil commotions,
strikes, lockouts or other labor disturbances, acts of God or acts, omissions or delays in acting by any governmental authority. The affected Party shall notify the other Party of such force majeure event as soon as reasonably practical, and shall
promptly undertake all commercially reasonable efforts to resolve such force majeure event. Should the event of force majeure suffered by a Party extend beyond a 120-day period, the other Party may then terminate this Agreement by written notice to
the non-performing Party, with the consequences of such termination as set forth in Sections 9.7 and 9.8. 
 11.3 Third
Parties. Nothing in this Agreement, express or implied, is intended to confer upon any party, other than the Parties hereto and their respective successors and permitted assigns, any rights, remedies, obligations or liabilities under or by
reason of this Agreement, except as otherwise provided in this Agreement with respect to Indemnitees under Article 8. 

11.4 Assignment. This Agreement may not be assigned or otherwise transferred, nor may any right or obligations hereunder be
assigned or transferred, by either Party to any Third Party without the prior written consent of the other Party; except that either Party may assign or otherwise transfer this Agreement without the consent of the other Party (a) to an entity
that acquires all or substantially all of the business or assets of the assigning Party relating to the subject matter of this Agreement, whether by merger, acquisition or otherwise, provided that intellectual property rights that are owned or held
by the acquiring entity (if other than one of the Parties to this Agreement) shall not be included in the technology subject to this Agreement, or (b) to an Affiliate, provided that the assigning Party shall remain liable and responsible to the
non-assigning Party for the performance and observance of all such duties and obligations by such Affiliate. Upon assignment, the rights and obligations under this Agreement shall be binding upon and inure to the benefit of said purchaser or
successor in interest. Any assignment of this Agreement in contravention of this Section 11.4 shall be null and void. 

  
 41 

 11.5 Notices. All notices, requests, demands and other communications required or
permitted to be given pursuant to this Agreement shall be in writing and shall be deemed to have been duly given upon the date of receipt if delivered by hand, overnight courier or confirmed facsimile or electronic mail (email) transmission to the
following addresses or facsimile numbers: 
  

			
	 If to Novus:
	  	If to Verenium:
		
	Novus International, Inc.	  	Verenium Corporation
	 20 Research Park Drive
 St.
Charles, Missouri 63304
	  	 4955 Directors Place
 San
Diego, California 92121

	Attention: General Counsel	  	Attention: Chief Executive Officer
	Tel: (314) 576-8419	  	
	Fax: (314) 576-4250	  	Fax: (858) 431-7272
	E-mail: Alice.Sterkel@novusint.com	  	E-mail: james.levine@verenium.com
		
	with a copy to:	  	with a copy to:
		
	 Polsinelli Shughart PC
 161 N.
Clark Ave., Suite 4200
 Chicago, IL 60601
	  	
		
	Attention: Teddy C. Scott	  	Verenium Corporation
	Tel: (312) 819-1900	  	4955 Directors Place
	Fax: (312) 873-2913	  	San Diego, California 92121
	E-mail: tscott@polsinelli.com	  	Attention: General Counsel
		  	Tel: (858) 431-8500
		  	Fax: (858) 876-9496
		  	E-mail: alex.fitzpatrick@verenium.com

 Either Party may change its designated address, facsimile number, or e-mail address by notice to the other Party in the
manner provided in this Section 11.5. 
 11.6 Governing Law. This Agreement shall be governed by and construed in
accordance with the laws of the State of New York, without reference to its conflicts of law principles with the exception of sections 5-1401 and 5-1402 of New York General Obligations Law (without limiting the Parties’ rights and obligations
under Article 10). The United Nations Conventions on Contracts for the International Sale of Goods shall not be applicable to this Agreement. 
 11.7 Amendment and Waiver. This Agreement may be amended, supplemented, or otherwise modified only by means of a written instrument signed by both Parties. Any waiver of any rights or failure to
act in a specific instance shall relate only to such instance and shall not be construed as an agreement to waive any rights or fail to act in any other instance, whether or not similar. 

  
 42 

 11.8 Severability. In the event that any provision of this Agreement shall, for any
reason, be held to be invalid or unenforceable in any respect, such invalidity or unenforceability shall not affect any other provision hereof, and the Parties shall negotiate in good faith to modify the Agreement to preserve (to the extent
possible) their original intent. 
 11.9 Relationship of Parties. It is expressly agreed that Verenium and Novus shall be
independent contractors and that nothing in this Agreement is intended or shall be deemed to constitute a partnership, agency, distributorship, employer-employee or joint venture relationship between the Parties. No Party shall incur any debts or
make any commitments for the other, except to the extent, if at all, specifically provided herein. 
 11.10 Entire
Agreement. This Agreement and the attachments and exhibits hereto and any letter delivering information referenced herein constitute the entire agreement between the Parties with respect to the subject matter hereof and supersede all prior and
contemporaneous agreements, representations, and understandings of the Parties with respect to the subject matter hereof, including the NDA. No Party hereto shall be liable or bound to the other in any manner by any warranties, representations or
covenants with respect to the subject matter hereof except as specifically set forth herein. 
 11.11 Headings. The
captions contained in this Agreement are not a part of this Agreement, but are merely guides or labels to assist in locating and reading the several Articles hereof. 
 11.12 Counterparts. This Agreement may be executed via facsimile and in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the
same instrument, and shall become effective when there exist copies hereof which, when taken together, bear the authorized signatures of each of the Parties hereto. Only one such counterpart signed by the Party against whom enforceability is sought
needs to be produced to evidence the existence of this Agreement. 
 11.13 Exports. The Parties acknowledge that the
export of technical data, materials, or Animal Feed Enzymes or Products is subject to the exporting Party receiving any necessary export licenses and that the Parties cannot be responsible for any delays attributable to export controls which are
beyond the reasonable control of either Party. Verenium and Novus agree not to export or re-export, directly or indirectly, any information, technical data, the direct product of such data, samples, Animal Feed Enzymes, Products or equipment
received or generated under this Agreement in violation of any applicable export control laws or governmental regulations. 

11.14 Language. The Parties hereto confirm their agreement that this Agreement, as well as any amendment hereto and all other
documents related hereto, including legal notices, have been and shall be in the English language only. 
 11.15 Limitation
of Liability for Indirect Damages. EXCEPT FOR AMOUNTS PAYABLE UNDER ARTICLE 4 OR FOR LIABILITY FOR BREACH OF CONFIDENTIALITY, IN NO EVENT WILL EITHER PARTY, ITS DIRECTORS, OFFICERS, EMPLOYEES, AGENTS OR AFFILIATES BE LIABLE TO THE OTHER PARTY
FOR ANY INDIRECT, INCIDENTAL, SPECIAL, EXEMPLARY, 

  
 43 

 
CONSEQUENTIAL, PUNITIVE OR MULTIPLE DAMAGES, OR FOR LOST PROFITS, LOST DATA OR LOSS OF USE DAMAGES, WHETHER BASED UPON A CLAIM OR ACTION OF CONTRACT, WARRANTY, NEGLIGENCE, STRICT LIABILITY OR
OTHER TORT, OR OTHERWISE, ARISING OUT OF THIS AGREEMENT. NOTHING IN THIS SECTION IS INTENDED TO LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS UNDER ARTICLE 8. 

(signature page follows) 

  
 44 

 IN WITNESS WHEREOF, the Parties have
executed this COLLABORATION AGREEMENT as of the Effective Date set forth above. 
  

									
	VERENIUM CORPORATION:	 		 	NOVUS INTERNATIONAL, INC.
					
	By:	 	 /s/ James E. Levine
	 		 	By:	 	 /s/ Giovanni Gasperoni

					
	Name:	 	 James E. Levine
	 		 	Name:	 	 Giovanni Gasperoni

					
	Title:	 	 President and Chief Executive Officer
	 		 	Title:	 	 Chief Administrative and Strategy Officer

 SIGNATURE PAGE TO COLLABORATION
AGREEMENT

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00198-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00198-of-00352.parquet"}]]